Total fat intake for the prevention of unhealthy weight gain in adults and children

WHO guideline
Total fat intake for the prevention of unhealthy weight gain in adults and children

WHO guideline
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgements</td>
<td>v</td>
</tr>
<tr>
<td>Abbreviations and acronyms</td>
<td>vi</td>
</tr>
<tr>
<td>Executive summary</td>
<td>vii</td>
</tr>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Background</td>
<td>1</td>
</tr>
<tr>
<td>Rationale</td>
<td>2</td>
</tr>
<tr>
<td>Scope</td>
<td>3</td>
</tr>
<tr>
<td>Objective</td>
<td>3</td>
</tr>
<tr>
<td>Target audience</td>
<td>4</td>
</tr>
<tr>
<td>How this guideline was developed</td>
<td>5</td>
</tr>
<tr>
<td>Contributors to the development of this guideline</td>
<td>5</td>
</tr>
<tr>
<td>Management of conflicts of interest</td>
<td>6</td>
</tr>
<tr>
<td>Guideline development process</td>
<td>6</td>
</tr>
<tr>
<td>Summary of evidence</td>
<td>9</td>
</tr>
<tr>
<td>Evidence to recommendations</td>
<td>15</td>
</tr>
<tr>
<td>Recommendations and supporting information</td>
<td>18</td>
</tr>
<tr>
<td>Uptake of the guideline and future work</td>
<td>21</td>
</tr>
<tr>
<td>References</td>
<td>24</td>
</tr>
<tr>
<td>Annexes</td>
<td>31</td>
</tr>
<tr>
<td>Annex 1: Members of the WHO Steering Group</td>
<td>33</td>
</tr>
<tr>
<td>Annex 2: Members of the guideline development group (NUGAG Subgroup on Diet and Health)</td>
<td>34</td>
</tr>
<tr>
<td>Annex 3: Members of the external peer review group</td>
<td>36</td>
</tr>
<tr>
<td>Annex 4: Summary and management of declarations of interests</td>
<td>37</td>
</tr>
<tr>
<td>Annex 5: Key question in PICO format</td>
<td>40</td>
</tr>
<tr>
<td>Annex 6: GRADE evidence profiles</td>
<td>41</td>
</tr>
<tr>
<td>Annex 7: Evidence to recommendations table</td>
<td>47</td>
</tr>
</tbody>
</table>
This guideline was prepared by the Department of Nutrition and Food Safety of the World Health Organization (WHO) under the overall leadership of Francesco Branca, Director of the Department of Nutrition and Food Safety, and the coordination of Chizuru Nishida. Jason Montez was the responsible technical officer. WHO gratefully acknowledges the contributions that many individuals and organizations have made to the development of this guideline.

**WHO Steering Group:** Ayoub Al-Jawaldeh, Anshu Banerjee, Hana Bekele, Fabio Da Silva Gomes, Jason Montez, Chizuru Nishida, Juan Pablo Peña-Rosas, Padmini Angela De Silva, Juliawati Untoro, Cherian Varghese, Kremlin Wickramasinghe

**Guideline Development Group (WHO Nutrition Guidance Expert Advisory Group – Subgroup on Diet and Health):** Hayder Al-Domi (University of Jordan, Jordan), John H Cummings (University of Dundee, United Kingdom of Great Britain and Northern Ireland), Ibrahim Elmadfa (University of Vienna, Austria), Lee Hooper (University of East Anglia, United Kingdom of Great Britain and Northern Ireland), Shiriki Kumanyika (University of Pennsylvania, United States of America), Mary L’Abbé (University of Toronto, Canada), Pulani Lanerolle (University of Colombo, Sri Lanka), Duo Li (Zhejiang University, China), Jim Mann (University of Otago, New Zealand), Joerg Meerpohl (University of Freiburg, Germany), Carlos Monteiro (University of Sao Paulo, Brazil), Laetitia Ouedraogo Nikièma (Institut de Recherche en Sciences de la Santé, Burkina Faso), Harshpal Singh Sachdev (Sitaram Bhartia Institute of Science and Research, India), Barbara Schneeman (University of California, Davis, United States of America), Murray Skeaff (University of Otago, New Zealand), Bruno Fokas Sunguya (Muhimbili University of Health and Allied Sciences, United Republic of Tanzania), HH (Esté) Vorster (North-West University, South Africa)

**External peer review group:** Hassan Aguenau (Ibn Tofaïl University, Morocco), Leanne Hodson (University of Oxford, United Kingdom of Great Britain and Northern Ireland), Tatsuya Koyama (Aomori University of Health and Welfare, Japan), Anna Larney (University of Ghana, Ghana), K. Srinath Reddy (Public Health Foundation of India, India), Juan Rivera (Instituto Nacional de Salud Pública, Mexico), Linda Snetselaar (University of Iowa College of Public Health, United States of America)

WHO would like to acknowledge the important contributions made by members of the systematic review teams (see pages 5–6). Additional thanks are also due to former interns of the Department of Nutrition and Food Safety: Angela Amico, Grace Carroll, Katharina da Silva Lopes and Yvonne Teng, for feedback on the draft guideline and various technical inputs.

WHO gratefully acknowledges the financial support provided by the Ministry of Health, Labour and Welfare of the Government of Japan for the guideline development work, including the systematic reviews, and by Qingdao University in China for hosting the 13th meeting of the WHO Nutrition Guidance Expert Advisory Group – Subgroup on Diet and Health in December 2019.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CVDs</td>
<td>cardiovascular diseases</td>
</tr>
<tr>
<td>eLENA</td>
<td>WHO e-Library of Evidence for Nutrition Actions</td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
</tr>
<tr>
<td>GINA</td>
<td>WHO Global Database on the Implementation of Nutrition Action</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations Assessment, Development and Evaluation</td>
</tr>
<tr>
<td>HDL</td>
<td>high density lipoprotein</td>
</tr>
<tr>
<td>kcal</td>
<td>kilocalories</td>
</tr>
<tr>
<td>kJ</td>
<td>kilojoules</td>
</tr>
<tr>
<td>LDL</td>
<td>low density lipoprotein</td>
</tr>
<tr>
<td>LMIC</td>
<td>low- and middle-income country</td>
</tr>
<tr>
<td>MD</td>
<td>mean difference</td>
</tr>
<tr>
<td>NCD</td>
<td>noncommunicable disease</td>
</tr>
<tr>
<td>NUGAG</td>
<td>WHO Nutrition Guidance Expert Advisory Group</td>
</tr>
<tr>
<td>PICO</td>
<td>population, intervention, comparator and outcome</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized controlled trial</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Executive summary

Background
Escalating rates of overweight and obesity are a threat to the health of billions of people across the globe. Obesity increases the risk of premature mortality and of many noncommunicable diseases (NCDs) including cardiovascular diseases (CVDs), type 2 diabetes and certain types of cancers; it also increases the risk of becoming severely ill from COVID-19.

Among other lifestyle and dietary factors, the macronutrient distribution of the diet (i.e. the percentage of carbohydrates, protein and fats) has been explored as a possible contributor to the development of overweight and obesity. Dietary fat and fatty acids are important in human physiology but are also the most energy dense of the macronutrients, and there has been extensive discussion of the potential impact of the percentage of calories consumed as fat on body weight. Because the role of dietary fat in the development of overweight and obesity continues to be debated, it was considered important to review the evidence in a systematic manner, and to update current WHO guidance on total fat through the WHO guideline development process.

Objective, scope and methods
The objective of this guideline is to provide updated guidance on the intake of total fat, to be used by policymakers, programme managers, health professionals and other stakeholders in efforts to promote healthy diets. The guidance was formulated based on evidence for unhealthy weight gain only. The guideline was developed following the WHO guideline development process, as outlined in the WHO handbook for guideline development. This process includes a review of systematically gathered evidence by an international, multidisciplinary group of experts; assessment of the quality of that evidence via the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework; and consideration of additional, potentially mitigating factors when translating the evidence into recommendations. The guidance in this guideline replaces previous WHO guidance on total fat intake, including that from the 1989 WHO Study Group on Diet, Nutrition and the Prevention of Chronic Diseases and the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases.

The evidence
Evidence from a systematic review of randomized controlled trials (RCTs) conducted in non-dieting adults found that reducing intake of total fat led to lower body weight, body mass index (BMI), waist circumference and percentage of body fat (high certainty evidence overall). Results of subgroup analyses and meta-regression suggest that greater reductions in total fat intake were associated with greater differences in body weight, and that those consuming less than 30% of total energy intake as fat had less body fatness than those consuming 30% or more of total energy intake as fat. There was no suggestion of undesirable

---

1 In this context, unhealthy weight gain refers to unintentional weight gain (i.e. increase in body fatness) that contributes to the progression towards overweight and obesity, but excludes appropriate weight gain during pregnancy and as part of normal growth and development in childhood. Other exceptions would include weight gain resulting from activities that increase muscle mass without increasing fat mass, such as weight-lifting and other strength-building exercise. For the development of this guideline, unhealthy weight gain was assessed as an increase in, or greater measures of, body fatness as reported in the systematic reviews underpinning the recommendations.

2 These include desirable and undesirable effects of the intervention, priority of the problem that the recommendations address, values and preferences related to the recommendations in different settings, the cost of the options available to public health officials and programme managers in different settings, feasibility and acceptability of implementing the recommendations in different settings, and the potential impact on equity and human rights.
effects associated with reduced fat intake that might mitigate any benefits on body fatness, including undesirable changes in blood lipids or blood pressure or negative effects on quality of life. In fact, a small improvement in total cholesterol, low density lipoprotein (LDL) cholesterol and blood pressure was observed with reduced fat intake.

Because of differences in methodology and data reporting across the studies, meta-analyses of identified prospective cohort studies could not be reliably conducted. Of the 39 reported analyses in 14 cohort studies on the association between total fat intake and measures of body fatness in adults, 12 suggested a positive association, three suggested a negative association and one was unclear. The remaining 23 analyses did not show statistically significant associations.¹

Three RCTs conducted in children were identified, but due to differential reporting of outcomes at different points of follow-up they were not considered suitable for meta-analysis. Results of RCTs on measures of body fatness were inconsistent but there was no suggestion of undesirable effects associated with reduced fat intake in terms of blood lipids or linear growth.

Recommendations and supporting information

These recommendations should be considered in the context of other WHO guidelines on healthy diets, including those on saturated fatty acids, trans-fatty acids, polyunsaturated fatty acids, sugars, carbohydrates, non-sugar sweeteners, sodium and potassium.

<table>
<thead>
<tr>
<th>WHO recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. To reduce the risk of unhealthy weight gain, WHO suggests that adults limit total fat intake to 30% of total energy intake or less (conditional recommendation)</td>
</tr>
<tr>
<td>2. Fat consumed should be primarily unsaturated fatty acids, with no more than 10% of total energy intake coming from saturated fatty acids and no more than 1% of total energy intake coming from trans-fatty acids (strong recommendation)</td>
</tr>
</tbody>
</table>

Rationale for recommendation 1

- This recommendation is based on evidence of high certainty from a systematic review of RCTs of dietary fat reduction in adults in which weight loss was not an explicit goal. All measures of body fatness assessed in the review (i.e. body weight, BMI, waist circumference and percentage body fat) were lower in adult participants randomized to a lower fat intake versus usual or moderate intake, with the most commonly reported measure being body weight. The evidence further suggests that the greater the difference in fat intake between those reducing fat intake and those not doing so, the greater the difference in body weight (i.e. a dose–response relationship), regardless of the final level of total fat intake achieved. Overall, the evidence suggests that a lower fat intake has the potential to help reduce the risk of unhealthy weight gain.

- The threshold of 30% was selected because most of the trials included in the analyses reported total fat intakes of 30% or more at baseline (range: 29–43% of total energy intake) and most studies achieved intakes of 30% or less in the intervention arms (range: 14–35% of total energy intake). When compared directly via subgroup analysis, there was a greater difference in body weight in trials where total fat intake was reduced to a final level of less than 30% of total energy intake in the intervention arms than in trials where total fat intake was reduced to a final level that was 30% of total energy intake or more in the intervention arms. In addition, the observed dose–response relationship indicates a cumulative effect of lower fat intake across the range of baseline intakes, with a greater reduction in fat intake resulting in a greater difference in body weight. Therefore, although an effect on body weight is anticipated with

¹ The evidence from cohort studies was reviewed but was not formally assessed for quality using GRADE methodology, given the inability to pool the effects of the identified cohort studies via meta-analysis, that the qualitative results from the cohort studies were consistent with those from the RCTs and that the data from the RCTs were robust and of higher certainty.
reducing total fat intake regardless of the level of total fat intake achieved, the greatest effect may be achieved with a reduction to 30% of total energy intake or less.

- The recommendation was assessed as *conditional* because some individuals who reduce their fat intake might replace some of the energy from dietary fat with energy from foods that are undesirable from a dietary quality perspective (e.g. free sugars), reducing the net benefit. It is therefore important to consider this recommendation in the context of other WHO dietary recommendations, including those on free sugars and carbohydrates, which provide guidance on carbohydrate quality. The evidence did not suggest any undesirable effects with respect to serum lipids, blood pressure or quality of life from lower total fat intake, but rather of small benefits or no effect (all *high* certainty evidence, except for quality of life, which was assessed as *low* certainty evidence). No mitigating factors were identified that would argue against limiting total fat intake to 30% of total energy intake or less.

**Remarks for recommendation 1**

- This recommendation is relevant for individuals aged 20 years or older.
- The goal in developing this guideline was to provide recommendations for both adults and children. However, the evidence was considered insufficient to support the formulation of a recommendation for children owing to the limited number of studies and inconsistent results identified for children, and the conclusion that the adult data could not reasonably be extrapolated to children given the unique energy requirements for optimal growth and development throughout childhood and adolescence. Previous expert consultations on dietary fats have concluded that for children aged 6 months and above and adolescents, total fat intakes of up to 35% of total energy are appropriate to meet growth demands without leading to excess energy intake.1

- The threshold of 30% in this recommendation should not be interpreted as an upper value of intake to be achieved by increasing fat intake among those with nutritionally adequate total fat intakes that are already less than 30% of total energy intake.

- Evaluation of the evidence suggests that the observed effect of reducing total fat intake on measures of body fatness is mediated, at least in part, by dietary behaviours that affect energy balance. In most trials, those who reduced their total fat intake also decreased their total energy intake (even though that was not intended in the trial design), and this led to decreasing weight. This finding suggests that there may be a tendency for those habitually consuming greater amounts of total fat to also consume more energy than needed, resulting in excess energy intake and subsequent weight gain. However, individuals who can maintain energy balance (or otherwise prevent excess energy intake) at higher fat intakes may be able to consume total fat at levels greater than 30% of total energy intake without increasing their risk of unhealthy weight gain.

- The scope of this guideline was limited to developing recommendations for the prevention of unhealthy weight gain, not for the management of existing overweight or obesity. Therefore, studies conducted with overweight participants actively pursuing weight loss (i.e. “weight loss studies”) were not included in the systematic review used to inform the recommendation. The recommendation may therefore not apply to individuals actively pursuing weight loss through modification of the diet, although current evidence does suggest that lower fat, restricted-calorie diets may be one of several effective, short-term strategies for losing excess body weight.

- This recommendation should not be interpreted as implying that total fat is the only risk factor for unhealthy weight gain and that reducing total fat intake alone is sufficient to prevent unhealthy weight gain. The etiology of unhealthy weight gain is complex and can involve many different inputs. Therefore, this recommendation should be considered in the context of other relevant WHO guidance, including that on the intake of free sugars, carbohydrates, non-sugar sweeteners, energy requirements and physical activity.

---

1 Infants should be exclusively breastfed for the first 6 months of life to achieve optimal growth, development and health. Thereafter, to meet their evolving nutritional requirements, infants should receive nutritionally adequate and safe complementary foods, while continuing to breastfeed for up to 2 years or beyond.
Dietary fat, including essential fatty acids (which cannot be synthesized by the human body), is necessary for proper physiological function. To ensure an adequate intake of energy and essential fatty acids, and to facilitate the absorption of lipid-soluble vitamins, total fat intake in most adults should be at least 15–20% of total energy intake.

The decision to implement this recommendation must be made in the context of achieving or maintaining nutritional adequacy and avoiding excess energy intake. In populations where undernutrition is not prevalent, the recommendation can generally be safely implemented as needed, provided that individual energy requirements are met, and recognizing that energy requirements are increased in pregnant and lactating women. Consideration must be given to populations in which prevalence of undernutrition is a concern and where total fat intake may already be low. In such settings, maintaining or even increasing total fat intake of individuals (in line with guidance on fat quality in recommendation 2) may be important to achieve adequate energy intake, as well as maintain or improve the overall diet.

Rationale for recommendation 2

This recommendation is taken from recommendations found in the WHO guideline, *Saturated fatty acid and trans-fatty acid intake for adults and children* which are based on effects of these nutrients on mortality and CVD outcomes.

Remarks for recommendation 2

This recommendation is relevant for all individuals aged 2 years and older.

This recommendation, taken together with recommendation 1, acknowledges that both quantity and quality of fat consumed are important for health and nutritional well-being.

Further remarks may be found in the WHO guideline, *Saturated fatty acid and trans-fatty acid intake for adults and children*. 
Introduction

Background

Escalating rates of overweight and obesity are a threat to the health of billions of people across the globe. In 2016, more than 1.9 billion adults aged 18 years and older were overweight, of which more than 600 million were obese. In 2020, more than 38 million children under 5 years of age were overweight – an increase of nearly 6 million since 2000. High body mass index (BMI) was responsible for an estimated 4 million deaths in 2015, with greater increases in BMI in the overweight and obesity range leading to a greater risk of mortality. Obesity is also a risk factor for many noncommunicable diseases (NCDs) including cardiovascular diseases (CVDs), type 2 diabetes and certain types of cancers. NCDs are the leading causes of death globally and were responsible for an estimated 41 million (71%) of the 55 million deaths in 2019.

Obesity and certain NCDs also increase the likelihood of becoming severely ill from COVID-19 infection.

Among other lifestyle and dietary factors, macronutrient distribution of the diet (i.e. the percentage of carbohydrates, protein and fats) has been explored as a possible contributor to unhealthy weight gain, which may in turn lead to the development of overweight and obesity. Although BMI is increasing in almost every country, rates of overweight and obesity are growing most rapidly in low- and middle-income countries (LMICs) – settings where undernutrition is also still widely prevalent – thus fuelling growth of the double burden of malnutrition. Concurrent with this increase in unhealthy weight gain is a transition to diets higher in fat, salt and sugars (i.e. the “nutrition transition”), which has been extensively documented over the past two decades in numerous LMICs. Although the causes of increasing rates of overweight and obesity in LMICs are many and varied, an increase in total fat intake (primarily through increased consumption of animal fat and vegetable oils) has been described as a potential contributor.

Fats consumed by humans are generally in the form of triglycerides, which comprise three fatty acids attached to a glycerol molecule. The percentage of fat in the diet can be referred to as “total fat” and is the sum of all dietary fats, comprising monounsaturated and polyunsaturated fatty acids, saturated fatty acids and trans-fatty acids (without distinguishing between the different types of fat in terms of any associated health effects). Common sources of fat in the human diet are meat, fish, dairy products, plant- and animal-based oils and fats, nuts and seeds and highly processed foods.

In addition to being an important source of energy in the diet, fats and fatty acids play various roles in human physiology. They serve as a carrier for the fat-soluble vitamins A, D, E and K, and support their absorption and utilization.

---

1 Overweight and obesity are defined as follows:

- Children (<5 years):
  - Overweight: weight for height >+2 standard deviations (SD) of the World Health Organization (WHO) child growth standards median
  - Obesity: >+2 SD of the WHO growth reference for school-aged children and adolescents (equivalent to BMI 25 kg/m² at 19 years)

- School-aged children and adolescents (5–19 years):
  - Overweight: BMI-for-age >+1 SD of the WHO growth reference for school-aged children and adolescents (equivalent to BMI 23 kg/m² at 19 years)
  - Obesity: >+2 SD of the WHO growth reference for school-aged children and adolescents (equivalent to BMI 30 kg/m² at 19 years)

- Adults (≥20 years):
  - Overweight: BMI ≥25 kg/m²
  - Obesity: BMI ≥30 kg/m²

2 In this context, unhealthy weight gain refers to unintentional weight gain (i.e. increase in body fatness) that contributes to the progression towards overweight and obesity, but excludes appropriate weight gain during pregnancy and as part of normal growth and development in childhood. Other exceptions include weight gain resulting from activities that increase muscle mass without increasing fat mass, such as weight-lifting and other strength-building exercise. For the development of this guideline, unhealthy weight gain was assessed as an increase in, or greater measures of, body fatness as reported in the systematic reviews underpinning the recommendations.
Total fat intake for the prevention of unhealthy weight gain in adults and children: WHO guideline

Absorption in the intestine. Fatty acids are also an integral structural component of cell membranes and can differentially affect membrane function, depending on the nature of the individual fatty acids included therein. Many fatty acids have hormone-like or inflammatory properties and may be involved in diverse physiological processes such as immune function, wound healing and regulation of gene expression. Certain fatty acids are important for growth and development of the nervous system in utero and through the first months of life, and others may affect the risk of developing certain NCDs later in life.

Although dietary fats are essential for normal physiological function, they are the most energy dense of the macronutrients, supplying 9 kcal (37.7 kJ) of energy per gram. Because foods rich in fat are highly palatable, they may have a weaker effect on short-term satiety than foods with low or no fat content, particularly those containing greater amounts of protein or dietary fibre, although there is some evidence to suggest that dietary fat may help to promote longer term satiety (29, 30). Thus, higher fat intakes can lead to increased total energy intake (31–41), which in turn may lead to energy imbalance and unhealthy weight gain (42–44).

Several recent studies have shown either no association between higher fat diets consisting predominantly of unsaturated fat of plant origin and weight gain, or decreased risk of weight gain (45–48), suggesting that quality of dietary fat may also be a factor in the impact of dietary fat on body weight. Additionally, evidence for the role that percentage of fat in the diet may play in helping to reach and maintain a healthy body weight in individuals actively pursuing weight loss is inconsistent, with some studies reporting lower body weight with higher fat diets, others reporting lower body weight with lower fat diets, and still others reporting equivalent weight loss regardless of fat percentage when total energy intake is reduced (49–54).

Despite longstanding dietary advice to limit total fat intake because of its potential role in the risk of developing NCDs as well as overweight and obesity, fat intake remains high in many parts of the world (55), exceeding values recommended by several expert meetings and consultations convened by World Health Organization (WHO) including the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases (56). Furthermore, emerging evidence suggests a potential future trend of increasing fat intake in the near term (57).

Rationale

Following the work of the 1989 WHO Study Group on Diet, Nutrition and Prevention of Noncommunicable Diseases (58), the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases updated the guidance on total fat intake as part of the guidance on population nutrient intake goals for the prevention of NCDs (56). In 2008, the Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition (59) concluded that there was little evidence to suggest a link between total fat intake and coronary heart disease or cancer. However, as a result of limited evidence and conflicting interpretations of the results regarding an association between total fat intake and body weight, the Expert Consultation was unable to reach a consensus conclusion; therefore, it maintained the recommended level of total fat intake established by the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases (56). The consultation noted that further research was needed, including a systematic review of available evidence on the effects of total fat intake on body weight, to develop globally applicable guidance on total fat intake.

Since that time, rates of overweight and obesity have continued to climb, and numerous studies and analyses of fat intake have been published, particularly in relation to a possible role in unhealthy weight gain. Consequently, the debate has continued as to whether the available evidence supports recommendations to lower or limit total fat intake. In addition, there has been a general transition to diets higher in fat, salt and sugars in many of the same LMICs (19–22) where overweight and obesity have become a major public health concern (15, 16). Evidence suggests that increased total fat intake (primarily through increased consumption of animal fat and vegetable oils) may be a contributor to increasing rates of overweight and obesity in LMICs (20, 24–27). Consequently, there has been great interest from Member States in addressing unhealthy weight gain in their populations through a variety of evidence-informed policies and actions. Therefore, it was considered important to review the existing evidence for total fat intake in the context of body fatness in a systematic manner, and update WHO’s guidance on total fat intake through the WHO guideline development process.
**Scope**

This guideline is part of the larger effort to update the population nutrient intake goals for the prevention of NCDs established by the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases (56). The focus of this guideline is on total fat intake and its effects on body fatness. It covers only the prevention of unhealthy weight gain and not the management of existing overweight or obesity. The recommendation on level of total fat intake in this guideline (recommendation 1) is intended for the general adult population. Owing to limited evidence, it was not possible to recommend a level of total fat intake for children. Recommendation 2 is intended for children and adults as indicated in the Remarks for recommendation 2. The guidance in this guideline replaces previous WHO guidance on total fat intake, including that from the 1989 WHO Study Group on Diet, Nutrition and the Prevention of Chronic Diseases (58) and the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases (56).

**Objective**

The objective of this guideline is to provide guidance on the intake of total fat as it relates to measures of body fatness. This is in recognition of the rapidly growing epidemic of obesity around the globe and its role as a risk factor for various NCDs. An additional key consideration of this guideline regarding risk of NCDs is to convey that the total amount of dietary fat (quantity) and the composition of dietary fat (quality) are tightly linked in their effects on health and are thus both important for overall guidance on dietary fat intake. Therefore, although quality of dietary fat is covered by other WHO guidance (56), it was considered important to communicate guidance on both quantity and quality of dietary fat in this guideline.

Updating the WHO recommendations for total fat intake is an important element of WHO’s efforts in implementing the NCD agenda and achieving the “triple billion” targets set by the 13th General Programme of Work (2019–2023), including 1 billion more people enjoying better health and well-being. In addition, the recommendations and other elements of this guideline will support:

- implementation of the political declarations of the United Nations (UN) high-level meetings on the prevention and control of NCDs held in New York in 2011 and 2018, and the outcome document of the high-level meeting of the UN General Assembly on NCDs (A/RES/68/300) held in New York in July 2014;
- implementation of the WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2030, which was adopted by the 66th World Health Assembly held in May 2013 (the timeline was extended to 2030 at the 72nd World Health Assembly held in May 2019);
- implementation of the recommendations of the high-level Commission on Ending Childhood Obesity established by the WHO Director-General in May 2014;
- Member States in implementing the commitments of the Rome Declaration on Nutrition and recommended actions in the Framework for Action, including a set of policy options and strategies to promote diversified, safe and healthy diets at all stages of life – these were adopted by the Second International Conference on Nutrition (ICN2) in 2014 and endorsed by the 136th Session of the WHO Executive Board held in January 2015 and the 68th World Health Assembly held in May 2015, which called on Member States to implement the commitments of the Rome Declaration across multiple sectors;
- achievement of the goals of the UN Decade of Action on Nutrition (2016–2025), declared by the UN General Assembly in April 2016, which include increased action at the national, regional and global levels to achieve the commitments of the Rome Declaration, through implementing policy options included in the Framework for Action and evidence-informed programme actions; and
- the 2030 Agenda on Sustainable Development and achieving the Sustainable Development Goals, particularly Goal 2 (Zero hunger) and Goal 3 (Good health and well-being).
**Target audience**

This guideline is intended for a wide audience involved in the development, design and implementation of policies and programmes in nutrition and public health. The end users for this guideline are thus:

- policy-makers at the national, local and other levels;
- managers and implementers of programmes relating to nutrition and NCD prevention;
- nongovernmental and other organizations, including professional societies, involved in managing and implementing programmes relating to nutrition and NCD prevention;
- health professionals in all settings;
- scientists and others involved in nutrition and NCD-related research;
- educators teaching nutrition and prevention of NCDs at all levels; and
- representatives of the food industry and related associations.
How this guideline was developed

This guideline was developed in accordance with the WHO evidence-informed guideline development process outlined in the *WHO handbook for guideline development* (60). Because of the complex nature of the guideline topic and the evolving evidence base, the guideline was developed over several meetings of the WHO Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health, beginning in 2016.¹

**Contributors to the development of this guideline**

This guideline was developed by the WHO Department of Nutrition and Food Safety (formerly the Department of Nutrition for Health and Development). Several groups contributed to the development of this guideline, and additional feedback was received from interested stakeholders via public consultation, as described below.

**WHO steering group**

The work was guided by an internal steering group, which included technical staff from WHO with varied perspectives and an interest in the provision of scientific advice on healthy diets (*Annex 1*).

**Guideline development group**

The guideline development group – the NUGAG Subgroup on Diet and Health – was convened to support the development of this guideline (*Annex 2*). This group included experts who had previously participated in various WHO expert consultations or were members of WHO expert advisory panels, and others identified through open calls for experts. In forming the group, the WHO Secretariat took into consideration the need for expertise in multiple disciplinary areas, representation from all WHO regions and a balanced gender mix. Efforts were made to include subject matter experts (e.g. in nutrition, epidemiology, paediatrics, physiology); experts in systematic review, programme evaluation and Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologies; and representatives of potential stakeholders (e.g. programme managers, policy advisers, other health professionals involved in the healthcare process). Professor Shiriki Kumanyika served as the chair at the meetings of the NUGAG Subgroup on Diet and Health. The names, institutional affiliations and summary background information of the members of the NUGAG Subgroup on Diet and Health are available on the WHO website,¹ along with information on each meeting of the group.

**External peer review group**

External experts with diverse perspectives and backgrounds relevant to the topic of this guideline were invited to review the draft guideline to identify any factual errors, and comment on the clarity of the language, contextual issues and implications for implementation (*Annex 3*).

**Systematic review teams**

Systematic review teams with expertise in both systematic review methodologies and the subject matter were identified.

¹ For a complete list of meetings and information on members of the NUGAG Subgroup on Diet and Health, see https://www.who.int/groups/nutrition-guidance-expert-advisory-group-(nugag)/diet-and-health.
A team from Norwich Medical School in the United Kingdom of Great Britain and Northern Ireland and University of Otago in New Zealand consisting of Lee Hooper, Asmaa Abdelhamid, Oluseyi Jimoh, Diane Bunn, and Murray Skeaff completed a systematic review on total fat intake and body fatness in adults (12, 13).

A team from Stellenbosch University in South Africa consisting of Celeste Naude, Marianne Visser, Kim Nguyen, Solange Durao, and Anel Schoonees completed a systematic review on total fat intake and body fatness in children (14).

Teams consulted frequently with the WHO Secretariat to ensure that the reviews met the needs of the WHO guideline development process.

**Stakeholder feedback via public consultation**

Two public consultations were held during the development of this guideline: one at the scoping phase of the process in early 2010 (feedback was received from a total of 15 individuals and organizational stakeholders) and one for the draft guideline in April 2021 (feedback was received from a total of 25 individuals and organizational stakeholders). Stakeholders and others with an interest in the guideline were invited to provide feedback on overall clarity, any potentially missing information, setting-specific or contextual issues, considerations and implications for adaptation and implementation of the guideline, and additional gaps in the evidence to be addressed by future research. The consultation was open to everyone. Declaration of interest forms were collected from all those submitting comments, which were assessed by the WHO Secretariat, following the procedures for management of interests described in the next section. Comments were summarized, and together with WHO responses to the summary comments, posted on the WHO website.1 Comments that helped to focus the scope of the guideline or improve clarity and usability of the draft guideline were considered in finalizing the scope and the guideline document.

**Management of conflicts of interest**

Financial and intellectual interests of the members of the NUGAG Subgroup on Diet and Health, those serving as external peer reviewers, and individuals who prepared systematic reviews or contributed other analyses were reviewed by members of the WHO Secretariat, in consultation with the WHO Department of Compliance and Risk Management and Ethics, where necessary. Declared interests of members of the NUGAG Subgroup on Diet and Health and of the systematic review teams were reviewed before their original engagement in the guideline development process and before every meeting. In addition, each member of the NUGAG Subgroup on Diet and Health (and members of the systematic review teams, if present) verbally declared their interests, if required, at the start of each meeting of the group. Declared interests of external reviewers were assessed before they were invited to review the draft guideline. In addition to reviewing interests declared by the individuals themselves, an internet search was conducted for each contributor to independently assess financial and intellectual interests for the 4 years before their engagement in the the development of the guideline, which was repeated as necessary. The overall procedures for management of interests outlined in the WHO handbook for guideline development (60) were followed.

Interests declared by members of the NUGAG Subgroup on Diet and Health, external reviewers and members of the systematic review teams, and the process for managing any identified conflicts of interest are summarized in Annex 4.

**Guideline development process**

**Scoping of the guideline**

The scientific literature was reviewed to identify important populations, outcomes and other topics relevant to the health effects of total fat intake. Existing systematic reviews on the topic were identified. The information gathered was compiled and used to generate the key questions and outcomes that would guide the selection of existing systematic reviews or the undertaking of new systematic reviews.

---

1 https://www.who.int/groups/nutrition-guidance-expert-advisory-group-(nugag)/diet-and-health
Defining key questions and prioritizing outcomes

Based on the outcomes of the 2008 Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition (59), requests from Member States to examine the evidence for the effects of total fat intake on body weight, and reviews of the scientific literature, WHO developed an initial set of questions to be addressed in the guideline and one outcome of interest on unhealthy weight gain1 (as assessed by various measures of body fatness including body weight, BMI, waist circumference, skinfold thickness and percentage body fat). The questions were based primarily on the needs of Member States and international partners for policy and programme guidance. The population, intervention, comparison and outcome (PICO) format was used in generating the questions (Annex 5). The PICO questions were first discussed and reviewed by the WHO Secretariat and the NUGAG Subgroup on Diet and Health, and were then made available for public comment.

The key questions that guided the systematic reviews undertaken are as follows.

- What is the effect of reduced intake of total fat on measures of body fatness in adults?
- What is the effect of reduced intake of total fat on measures of body fatness in children?

Evidence gathering and review

Two systematic reviews of randomized controlled trials (RCTs) and prospective cohort studies were commissioned to assess the effects of modifying intake of total dietary fat on unhealthy weight gain, as assessed by measures of body fatness in adults and children.

- A systematic review of RCTs and prospective cohort studies conducted in adults last updated in 2020 (13). This update was limited to RCTs, because the data for prospective cohort studies obtained in the original review (12) were too varied to synthesize and therefore did not provide useful information beyond that obtained from the RCTs.

- A systematic review of RCTs and prospective cohort studies conducted in children and published in 2018 (14). A subsequent scan of the literature covering the date the literature was searched for the original review through May 2021 was conducted and nothing was identified that would significantly change the results or conclusions of the original review. Therefore, this systematic review was not formally updated.

Assessment of certainty in the evidence

GRADE2 methodology was used to assess the certainty in the evidence (i.e. confidence in) identified in the systematic reviews. GRADE assessments assigned by the systematic review teams were discussed by the NUGAG Subgroup on Diet and Health and the systematic review teams, and refined as necessary under the guidance of a methodologist with extensive expertise in GRADE methodology. When assessing the overall certainty in the evidence for body fatness or undesirable effects, which consisted of several component outcomes, the certainty for each component outcome was assessed individually. Where all component outcomes showed the same direction of effect, the overall certainty in the main outcome was taken to be the highest certainty of the individual component outcome(s) which alone would be sufficient to base a recommendation on. GRADE assessments are summarized in Annex 6.

---

1 Unhealthy weight gain was selected as the priority outcome for the development of this guideline owing to conclusions drawn and recommendations made by the 2008 Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition (“Expert Consultation”) (59). The Expert Consultation concluded that from the available evidence reviewed at the time of the consultation there was little evidence to suggest a link between total fat intake and coronary heart disease or cancer. However, as a result of limited evidence and conflicting interpretation of the results regarding an association between total fat intake and body fatness, the Expert Consultation was unable to reach a consensus conclusion and therefore maintained the recommended level of total fat intake established by the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases (56). It was also noted that further research was needed, including a systematic review of available evidence on the effects of total fat intake on body fatness, to develop globally applicable guidance on total fat intake. Therefore, in developing the WHO guideline on total fat intake, including the undertaking of a new systematic review, the NUGAG Subgroup on Diet and Health focused on unhealthy weight gain (as an indication of unhealthy increase in body fatness) as the priority outcome.

2 See http://www.gradeworkinggroup.org/
Formulation of the recommendations

In formulating the recommendations and determining their strength, the NUGAG Subgroup on Diet and Health assessed the evidence in the context of the certainty in the evidence, desirable and undesirable effects of the intervention, priority of the problem that the intervention would address, values and preferences related to the effects of the intervention in different settings, the cost of the options available to public health officials and programme managers in different settings, the feasibility and acceptability of implementing the intervention in different settings, and the potential impact on equity and human rights (Annex 7).

Supported by a dose–response relationship observed between total fat intake and body weight, the NUGAG Subgroup on Diet and Health concluded that an individual target would be easier to implement than a population goal, particularly in terms of updating food-based dietary guidelines, education and awareness campaigns and other interventions aimed at eliciting desired behavioural change at the individual level. Therefore, the recommended level of total fat intake is a target for individuals to achieve rather than a population goal. Based on the evidence and additional factors, the NUGAG Subgroup on Diet and Health developed the recommendations and associated remarks by consensus.
Summary of evidence

Two systematic reviews of RCTs and prospective cohort studies were conducted to assess the effects of modifying intake of total dietary fat on unhealthy weight gain as assessed by relevant health outcomes in adults (12, 13) and children (14).

Adults

RCTs

A systematic review of RCTs assessing the effects of reducing intake of total fat on body fatness in adults was conducted (12, 13). Because the focus of this guideline is on prevention of unhealthy weight gain, and not on the management of existing overweight or obesity, trials were excluded from the systematic review if the aim was intentional weight loss of participants in the intervention arm, or if participants were selected for higher body weight, BMI or body weight classification (as most appeared to have weight loss goals, even when this was not explicitly stated). Trials with participants of mixed body weights (including those with overweight and obesity) that met the other inclusion criteria were included. Only trials in which the dietary intervention lasted at least 6 months were included in the review (trial duration ranged from 6 months to more than 8 years).

The systematic review included 37 RCTs with over 57,000 participants. Of these, 24 were conducted in North America, 10 in Europe, two in Australia and New Zealand, and one in China. In four trials the participants were all men, in 16 all women, and in 17 both sexes (one of which reported outcomes separately by sex). Mean ages and states of health (i.e. low, moderate or high risk of CVDs or breast cancer) varied. In the included trials, intervention arms consisted of participants who reduced total fat intake as a percentage of total energy intake (“reduced fat arms”) as a result of interventions including the receipt of dietary advice or provision of food (i.e. either supplementation with fats, oils or modified or low-fat foods, or a complete diet), and control arms consisted of participants who retained their usual fat intake (i.e. did not receive a reduced fat intervention). Total fat intake at baseline was 29–43% of total energy intake. Achieved intakes of total dietary fat were 14–35% of total energy intake across intervention and control arms of the trials.

Body weight

Meta-analysis of RCTs found that reducing total fat intake resulted in a lower body weight in reduced fat arms compared with control arms (mean difference [MD] –1.42 kg; 95% confidence interval [CI]: –1.73 to –1.10; 26 trials/33 comparisons with 53,875 participants). The effect on body weight was consistent across the trials, with a lower body weight in reduced fat arms reported in 30 of the 33 comparisons included in the

1 Such trials were potentially confounded by the implicit objective of reducing energy intake to produce weight loss and might therefore lead to an overemphasis on trials carried out exclusively in highly selected overweight and obese populations, which may have limited applicability in non-overweight populations, including those in some LMICs. The decision to exclude studies with intentional weight loss goals was carefully considered because it was realized that doing so would exclude many studies assessing the effect of reducing total fat intake on body weight. However, it was determined that the inclusion of studies with intentional weight loss would not only skew the analysis to highly selected overweight and obese individuals but would also likely introduce bias that would decrease confidence in the results. This is because weight loss studies conducted in free-living individuals are frequently confounded by numerous, complex behavioural factors, including variability in motivation to adhere to a particular diet over time – which can be influenced by popular perception of its efficacy – as well as guilt if participants are unsuccessful in adhering to a particular diet, both of which could affect reporting of dietary intake. Results of weight loss studies in some cases could therefore reflect popularity of a particular diet more so than the body weight-altering effects of the macronutrients contained therein (61).

2 The differences in measures of body fatness reported at the conclusion of the individual trials varied in terms of how the difference was achieved. In some trials, the relative reduction in body weight was due to a smaller increase in body weight over time in the reduced fat arms than in the control arms, and in others, body weight was reduced in the intervention arms but decreased by less, stayed the same or increased in the control arms.
meta-analysis. In addition, nine trials, for which an estimable effect size could not be extracted due to lack of variance data or large baseline differences (and therefore did not contribute to the pooled effect), were consistent with lower body weights in the reduced fat arms compared with the control arms.

The effect of reducing total fat intake on body weight remained statistically significant in sensitivity analyses, including the exclusion of trials that:

- reported systematic differences in care; that is, greater time or resources were provided to the reduced fat arm than to the control arm (MD \(-0.89\) kg; 95% CI: \(-1.17\) to \(-0.60\));
- included additional dietary interventions to that of reducing total dietary fat intake\(^1\) (MD \(-1.63\) kg; 95% CI: \(-2.07\) to \(-1.19\)); or
- had potential compliance problems (MD \(-1.56\) kg; 95% CI: \(-1.88\) to \(-1.23\)).

The effect body weight also remained statistically significant in sensitivity analyses when:

- the largest trial (62) was excluded (MD \(-1.51\) kg; 95% CI: \(-1.86\) to \(-1.15\));
- included trials were limited to those with the lowest summary risk of bias\(^2\) (MD \(-0.67\) kg; 95% CI: \(-0.82\) to \(-0.52\)); or
- the data were analysed with a fixed-effects model rather than a random-effects model (MD \(-0.94\) kg; 95% CI: \(-1.05\) to \(-0.82\)).

Results of meta-regression analysis suggested that the magnitude of the difference in body weight was positively correlated with the magnitude of reduction in total fat intake, with greater reduction in total fat intake associated with greater differences in body weight (i.e. a dose–response relationship). The regression model indicates that for each 1% reduction in total fat intake, there is a decrease in body weight of 0.20 kg (95% CI: \(-0.34\) to \(-0.06\); \(P = 0.007\)), which suggests that any level of reduction in total fat intake is likely to result in some reduction in unhealthy weight gain. Results of prespecified subgroup analyses were further suggestive of a dose–response relationship between the magnitude of reduction in total fat intake and the magnitude of the difference in body weight, with the difference in body weight observed for differences in total fat intakes between reduced fat and control arms of:

- 5% to less than 10% of total energy intake (MD \(-1.76\) kg; 95% CI: \(-2.25\) to \(-1.28\));
- 10% to less than 15% of total energy intake (MD \(-1.23\) kg; 95% CI: \(-1.72\) to \(-0.74\)); and
- 15% of total energy intake or more (MD \(-3.91\) kg; 95% CI: \(-7.61\) to \(-0.22\));

being greater than the difference in body weight observed for a difference of less than 5% of total energy intake between reduced fat and control arms, which was not statistically significant (MD \(-0.15\) kg; 95% CI: \(-0.77\) to \(0.47\)) (test for subgroup differences \(P = 0.0005\)). Results of subgroup analyses further suggested greater difference in body weight in those achieving a total fat intake of 30% of total energy or less (MD \(-1.55\) kg; 95% CI: \(-1.93\) to \(-1.18\)), compared with those who did not achieve that target (i.e. achieved a total fat intake of more than 30% of total energy) (MD \(-0.90\) kg; 95% CI: \(-1.32\) to \(-0.47\)) (test for subgroup differences \(P = 0.02\)).

Results of subgroup analyses also indicated greater differences in body weight with greater reductions in total energy intake in the reduced fat arms of the trials, suggesting that the effect of lowering total fat intake on body weight might be mediated in part by a reduction in total energy intake – noting however, that dietary intake data from many studies included in the review are not robust and therefore reported energy intakes may not be precise. The difference in body weight between reduced fat and control arms was greater when energy intake was reduced in the reduced fat arm by:

- 1–100 kcal per day (MD \(-1.04\) kg; 95% CI: \(-1.68\) to \(-0.41\));
- 101–200 kcal per day (MD \(-0.74\) kg; 95% CI: \(-1.38\) to \(-0.10\)); or
- more than 200 kcal per day (MD \(-2.22\) kg; 95% CI: \(-2.83\) to \(-1.61\));

\(^1\) As an example, trials in which the intervention arm was advised to reduce total dietary fat intake and also encouraged to consume fruits and vegetables, compared with just being encouraged to consume fruits and vegetables in the control arm.

\(^2\) Trials with low risk of selection bias (low risk from random sequence generation and allocation concealment) and low risk of detection bias.
compared with the difference in body weight between reduced fat and control arms when total energy intake
did not differ or was greater in the reduced fat arm (MD –0.59 kg; 95% CI: –0.85 to –0.32) (test for subgroup
differences $P < 0.0001$). Where energy intake was not reported or was unclear, the MD in body weight was
–2.07 kg (95% CI: –3.33 to –0.80). The small, but statistically significant difference in body weight in reduced
fat arms that did not reduce total energy intake relative to the control arms suggests that although energy
intake may be an important pathway by which reduced total fat intake leads to less unhealthy weight gain,
other unidentified mechanisms may also be involved.

Results from the meta-regression found that the following were also significantly associated with the
magnitude of the difference in body weight in the reduced fat arms:

- total fat intake at baseline (suggesting that a reduction in fat intake was more effective at reducing
  unhealthy weight gain in those with a lower baseline fat intake); and
- baseline BMI (suggesting that a reduction in fat intake was more effective at reducing unhealthy weight
  gain in those with a higher BMI at baseline).

Results from subgroup analysis further supported these observations in that, generally speaking, a greater
difference in body weight was observed with lower baseline intakes and higher baseline BMI, although no
clear, cumulative progression in body weight difference was observed for either, and significantly lower
body weights were observed in reduced fat arms for all baseline intake and BMI subgroups (test for subgroup
differences for baseline total fat intake $P < 0.00001$, and baseline BMI $P = 0.06$).

Subgroup analyses also indicated significant effects on body weight in subgroups varying by:

- duration, suggesting that greatest effects on body weight may occur 12 to 24 months from first reducing
  fat intake, but without any clear indication of a dose–response relationship (i.e. greater differences in
  body weight with longer duration, or vice versa) and with lower body weight in all subgroups (test for
  subgroup differences $P = 0.04$);
- intervention type, with the greatest difference in body weight resulting from dietary advice, less from
  advice plus supplementary foods, and least when all foods were provided, noting that the number
  of studies in the dietary advice group was much greater than the other subgroups (test for subgroup
  differences $P = 0.0002$);
- baseline health status, with people recruited for having a long-term condition or risk factors for such a
  condition appearing to experience less unhealthy weight gain than those who were healthy at baseline
  (test for subgroup differences $P = 0.03$); and
- target fat intake in reduced fat arm, with lower body weight in all subgroups (except for two studies
  in which the target for fat reduction could not clearly be identified), but without any clear indication
  of a dose–response relationship (i.e. greater difference in body weight with larger target of fat intake
  reduction, or vice versa) (test for subgroup differences $P = 0.007$).

Results of subgroup analyses by sex or decade of publication were not significant, suggesting that the effect
of reducing fat intake did not differ between males and females or at different points in time when average
diets may have been different.

Other measures of body fatness

Fewer studies reported BMI than body weight, but the effect of a lower proportion of energy from fat on BMI
appeared to be consistent with that observed for body weight (MD –0.47 kg/m$^2$; 95% CI: –0.64 to –0.30; 14
trials/17 comparisons with 46 539 participants). The effect on BMI was consistent across the trials, with a
difference in BMI reported in 15 of the 17 comparisons, including one trial that could not be included in the
meta-analysis due to a lack of data on variance (63).

Few studies also reported on waist circumference and percentage of body fat. Meta-analysis found that
waist circumference in those on reduced fat diets was significantly lower than in those on usual fat diets (MD
–0.47 cm; 95% CI: –0.73 to –0.22; 3 trials with 16 620 participants) as was percentage of body fat, which was
only marginally significant (MD –0.28% body fat; 95% CI: –0.57 to 0.00; 2 trials with 2350 participants). One
trial that did not provide variance data and therefore could not be included in the meta-analyses reported
less of a decrease in waist circumference (−0.4 cm in the reduced fat arm and −1.1 cm in the control arm) and percentage of body fat (−0.4% in the reduced fat arm and −0.6% in the control arm) in the reduced fat arm compared with the control arm (63).

**Potential undesirable effects**

There was no suggestion of undesirable effects associated with reduced fat intake that might mitigate any benefits on body fatness, including undesirable changes in blood lipids or blood pressure or negative effects on quality of life. Compared with usual fat intake, reduced total fat intake resulted in small reductions in:

- total cholesterol (MD −0.23 mmol/L; 95% CI: −0.32 to −0.14; 22 trials/27 comparisons with 9812 participants);
- LDL cholesterol (MD −0.13 mmol/L; 95% CI: −0.21 to −0.05; 18 trials/21 comparisons with 8072 participants);
- systolic blood pressure (−0.75 mmHg; 95% CI: −1.42 to −0.07; 10 trials/13 comparisons with 6013 participants); and
- diastolic blood pressure (−0.52 mmHg; 95% CI: −0.95 to −0.09; 10 trials/13 comparisons with 6013 participants).

There was little to no effect on:

- high density lipoprotein (HDL) cholesterol (MD −0.02 mmol/L; 95% CI: −0.03 to 0.00; 20 trials/24 comparisons with 8268 participants);
- triglycerides (MD 0.01 mmol/L; 95% CI: −0.05 to 0.07; 18 trials/21 comparisons with 8607 participants); or
- total cholesterol/HDL cholesterol ratio (MD −0.05; 95% CI: −0.14 to 0.04; 5 trials/8 comparisons with 3639 participants).

Global or overall quality of life was assessed in one study, the Women's Health Initiative (64), in which the focus was on total fat reduction with little attention to the quality or type of fat being consumed. The study suggested very small improvements in those in the reduced fat arm compared with the control arm as assessed on a scale of 0 to 10, with 0 being worst and 10 best (MD 0.04, 95% CI: 0.01 to 0.07; 1 trial with 40 130 participants).

The overall certainty in the available evidence for an effect of reducing total fat intake on outcomes in adults was assessed as high,1 except for percentage body fat and quality of life, which were assessed as moderate and low, respectively.

**Cohort studies**

Fourteen adult cohorts were identified that reported on baseline total fat intake and reported on a measure of body fatness (i.e. body weight, BMI or waist circumference) at least 1 year later, representing 39 separate analyses. Cohorts were recruited in North America, Europe and Australia and follow-up ranged from 1 year to over 16 years, with a median of 5 years. Given the differences in methodology and data reporting across the studies, meta-analysis could not be reliably conducted. Of the 39 reported analyses of the association between total fat intake and measures of body fatness in adults, 12 suggested a positive association, three suggested a negative association and one was unclear. The remaining 23 analyses did not show statistically significant associations.

Because several of the trials were of sufficiently long duration for the NUGAG Subgroup on Diet and Health to be comfortable with the results reflecting a longer-term effect on weight loss, the evidence from

---

1 Based on the grades of evidence set by the GRADE Working Group: high certainty, we are very confident that the true effect lies close to that of the estimate of the effect; moderate certainty, we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low certainty, our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; very low certainty, we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect (60).
cohort studies was mixed and not amenable to meta-analyses but was generally not inconsistent with the evidence obtained from the analyses of RCTs, and the RCT evidence was of much higher quality than that of the cohort studies, lesser emphasis was placed on these results when formulating recommendations and consequently the results from this review are not reported in the GRADE evidence profiles.

Children

RCTs

A systematic review of RCTs assessing the effects of reducing intake of total fat on measures of body weight and fatness in children identified three RCTs with 1054 participants from high-income countries (14). However, because the RCTs reported different outcomes at different follow-up points, the studies were considered unsuitable for meta-analysis.

Interventions included family-based and school-based dietary advice and counselling. As the focus of this guideline is on prevention of unhealthy weight gain, and not on the management of overweight and obesity, trials in which the interventions were designed to result in intentional weight loss of participants, as well as trials where participants were chosen for raised body weight, BMI or body weight classification (as most appeared to have weight loss goals, even when this was not explicitly stated), were excluded. Only trials in which the dietary intervention lasted at least 6 months were included in the review (trial duration was 1–7 years). All three RCTs compared children with lower total fat intake (30% or less of their total daily energy) to children with usual or modified fat intake (more than 30% of their total daily energy). One trial was conducted in Greece and two in the United States of America. Overall, one RCT found that reduced intake of total fat resulted in decreased BMI over 1 year of follow-up, while a second found no effect on BMI with up to 7 years of follow-up. One RCT found no difference in body weight with reduced fat intake with up to 7 years of follow-up and another found no difference in weight-for-age z-scores at 1 year of follow-up.

Measures of body fatness

The VYRONAS trial randomized 218 students aged 12–13 years at baseline and with no known CVD risk factors to a 12-week school-based health and nutrition interventional programme or usual care, with a 1-year follow-up period (65). Total fat intake in the intervention arm decreased significantly ($P < 0.001$) while in the control arm it did not. At 1 year of follow-up, mean BMI (adjusting for age and sex) in the intervention arm was 1.5 kg/m² lower than the control arm (95% CI: $-2.45$ to $-0.55$; 191 participants).

The Dietary Intervention Study in Children (DISC) randomized 663 boys and girls aged 7–11 years at baseline with elevated serum LDL cholesterol levels to a nutrition counselling programme or usual care with a focus on specifically reducing saturated fatty acid intake, with up to 7 years of follow-up (66). At 3 years of follow-up, total fat intake in the intervention arm was significantly lower than in the control arm ($P < 0.01$). No significant difference was reported for body weight at 1 year of follow-up (MD $-0.50$ kg; 95% CI: $-1.78$ to $0.78$; 620 participants) or 3 years of follow-up (MD $-0.60$ kg; 95% CI: $-2.39$ to $1.19$; 612 participants), or for BMI at 1 year of follow-up (MD $-0.30$ kg/m²; 95% CI: $-0.75$ to $0.15$; 620 participants), 3 years of follow-up (MD $0.0$ kg/m²; 95% CI: $-0.63$ to $0.63$; 541 participants), or at the last visit (approximately 7 years of follow-up) (MD $-0.10$ kg/m²; 95% CI: $-0.75$ to $0.55$; 576 participants).

The Children’s Health Project randomized 271 boys and girls aged 4–11 years with elevated serum LDL cholesterol levels to a nutrition counselling programme or usual care with 1 year of follow-up (67). No significant difference between intervention and control arms was observed for weight-for-age z-scores at 1 year of follow-up (MD $-0.18$; 95% CI: $-0.51$ to $0.15$; 151 participants).

The overall certainty in the available evidence for an effect of reducing total fat intake on BMI and body weight in children was assessed as low, and for weight-for-age z-score it was assessed as very low.

Potential undesirable effects

The evidence did not suggest any undesirable effects of reducing total fat intake with respect to blood lipids, rather it suggested a small benefit or no effect. Compared with usual fat intake, reduced total fat intake resulted in small reductions in total cholesterol (MD $-0.15$ mmol/L; 95% CI: $-0.24$ to $-0.06$; 618 participants; moderate certainty) at 1 year of follow-up, and LDL cholesterol at 1 year of follow-up (MD...
-0.12 mmol/L; 95% CI: -0.20 to -0.04; 618 participants; moderate certainty) and 3 years of follow-up (MD -0.09 mmol/L; 95% CI: -0.17 to -0.01; 623 participants; moderate certainty). No effects were observed for total or LDL cholesterol at later timepoints, or for HDL cholesterol or triglycerides at any timepoint (low to moderate certainty). There was a small decrease in height for age z-score (MD -0.09 mmol/L; 95% CI: -0.17 to -0.01; 623 participants; moderate certainty) assessed at 1 year of follow-up, but no effects on height at any timepoint assessed (low certainty).

**Cohort studies**

Twenty-one cohorts that recruited children and young people were identified that reported on baseline total dietary fat intake and reported on a measure of body fatness (i.e. body weight, BMI or waist circumference) from one to 17 years later. Cohorts at baseline consisted of children aged 2–19 years, recruited in Australia, Europe, North America and the Republic of Korea. Given the differences in methodology and data reporting across the studies, meta-analysis could not be reliably conducted. Over half of the cohort analyses that reported on primary outcomes suggested that as total fat intake increases, measures of body fatness may also increase.

Given the inability to pool the effects of the identified cohort studies via meta-analysis, the evidence from cohort studies was not assessed for quality using GRADE methodology.
Evidence to recommendations

In translating the evidence into recommendations, the NUGAG Subgroup on Diet and Health assessed the evidence in the context of the certainty in the evidence, desirable and undesirable effects of the interventions, the priority of the problem that the interventions would address, values and preferences related to the effects of the interventions in different settings, the feasibility and acceptability of implementing the interventions in different settings, the potential impact on equity and human rights, and the cost of the options available to public health officials and programme managers in different settings.

Because the recommended “interventions” in this guideline are in fact dietary goals, they can be translated into policies and actions in a number of ways, including behaviour change interventions, fiscal policies, regulation of marketing, labelling schemes and reformulation of manufactured products, among others. Because each of these interventions has its own substantial evidence base (which was not reviewed by the NUGAG Subgroup on Diet and Health) and requires individual consideration of the additional evidence to recommendation factors, a detailed discussion of these factors for each of the possible interventions is beyond the scope of this guideline. However, forthcoming WHO guidelines will provide specific guidance on nutrition labelling policies, policies on marketing of food and non-alcoholic beverages to children, fiscal and pricing policies, and school food and nutrition policies, which will enable policy-makers to translate dietary goals into evidence-informed policies. 1 Therefore, in assessing the factors relevant to translating the evidence into recommendations for this guideline, the NUGAG Subgroup on Diet and Health primarily considered each recommendation in the context of achieving the recommended dietary goals.

Evidence for this process was gathered via comprehensive searches of relevant scientific databases and identification of high-quality studies, including recent systematic reviews, where available. An evidence to recommendation table can be found in Annex 7. 2

Overall certainty in the evidence

The certainty in the effects for body weight, BMI and waist circumference was assessed as high, and for percentage of body fat as moderate. Because beneficial effects were observed for all outcomes, the overall certainty was assessed as high. There was high certainty in the evidence for all outcomes related to potential undesirable effects, except for quality of life, which was as assessed as low. Because no undesirable effects were observed, the overall certainty was as assessed as high.

Balance of desirable and undesirable effects

Although the effects observed for body measures of body fatness were small to modest in magnitude, they were highly significant and resistant to sensitivity analyses. No undesirable effects were observed as measured by blood lipids, blood pressure and quality of life; in fact, small improvements were observed for total cholesterol, LDL cholesterol and blood pressure. The effect observed for body fatness is expected to make a positive impact on unhealthy weight gain, particularly when paired with other healthy diet and lifestyle interventions. Therefore, as reviewed directly in this body of evidence, the desirable effects strongly outweighed the non-existent undesirable effects. However, the NUGAG Subgroup on Diet and Health acknowledged that some individuals who reduce their fat intake might replace some of the energy

---

1 https://www.who.int/groups/nutrition-guidance-expert-advisory-group-(nugag)/policy-actions
2 Evidence to recommendation information is summarized in this section only for recommendation 1. Evidence to recommendation information for recommendation 2 can be found in the WHO guideline Saturated fatty acid and trans-fatty acid intake for adults and children (68).
from dietary fat with energy from foods that are undesirable from a dietary quality perspective, such as free sugars (69), reducing the net benefit.

Conversely, because some foods containing significant amounts of fat are also high in sugars or sodium or are otherwise consumed alongside other unhealthy foods, the undesirable effects of not following the recommendation for total fat intake may be compounded by undesirable effects (not necessarily limited to unhealthy weight gain) resulting from the accompanying higher intakes of sugars, sodium and unhealthy foods in general. Unhealthy eating patterns have been documented in many settings and pose a significant and growing public health problem, particularly in many LMICs (70). It was also noted that reducing total fat intake might lead to undesirable effects in those who are undernourished. Therefore, special consideration must be given to undernourished individuals and in some such cases the recommendations may not be appropriate. However, in the general population it was felt that the balance between desirable and undesirable effects favours the intervention.

Priority of the problem and values and preferences

These recommendations address overweight and obesity by way of unhealthy weight gain. Overweight and obesity are highly prevalent and increasing globally, particularly in LMICs (15–17); therefore, interventions to prevent unhealthy weight gain are valuable in all contexts and preventing unhealthy weight gain is a high priority for many countries. Despite the rising global prevalence of overweight and obesity, the priority placed on this problem by national authorities may vary depending on the real or perceived magnitude of the problem within each country. However, in the context of the COVID-19 pandemic, the importance of prevention of overweight and obesity has been highlighted because there is increasing recognition of obesity as an important, independent prognostic factor and COVID-19 patients with obesity are at increased risk for adverse outcomes (71).

The recommendations in this guideline place a high value on reducing unhealthy weight gain because it may contribute to reducing the prevalence of overweight and obesity, which will not only increase the risk of various NCDs, but also the severity of COVID-19. While individuals almost universally value the prevention of premature mortality, those that may be affected by the recommendation may value the benefit of reducing risk of obesity and associated disease differently based on personal preferences, beliefs and customs. For example, because CVDs are a high profile public health topic, including in many LMICs where they represent a growing threat (72), it is expected that most individuals would value efforts to reduce risk; however, in real-world settings, perception of the risk varies considerably (73–77) and may require outreach and communication efforts to improve understanding. Similarly, although many people in LMICs are increasingly aware of the negative health effects associated with being overweight or obese, some cultures still consider overweight to be a desirable or positive attribute (78–80). Others believe body weight to be hereditary and therefore not amenable to management via lifestyle changes (77, 81). And many, regardless of personal beliefs, incorrectly perceive their own body weight in the context of overweight and obesity (i.e. they believe they are at a healthy body weight when in fact they are overweight or obese according to accepted standards for assessing body weight outcomes) (77, 81, 82).

Feasibility

In settings where efforts to reduce total fat intake are planned or are already underway, feasibility should be much higher than in settings where plans are not yet in place. Regardless, feasibility will be influenced by the existing, relevant infrastructure (for different interventions) and resources available. In terms of implementing interventions to affect the desired change in total fat intake (e.g. behaviour change and education campaigns, fiscal policies, marketing and labelling policies, and reformulation), feasibility will vary widely and detailed discussions of feasibility for each are beyond the scope of this guideline.

Relevant to all interventions, widespread use and availability of certain food items high in fat may pose challenges in decreasing consumption where necessary to meet the recommended intake. Regardless of which interventions are employed to realize the recommended fat intake, some amount of behaviour change at the individual level will be required. This may be challenging in some settings, particularly those in which popular opinion has currently been shaped to view high fat intake as healthy, particularly with respect to losing weight or maintaining a healthy body weight (83).
Acceptability

The recommendations in this guideline are in line with many existing national dietary guidelines and policies, however, acceptability may vary across different countries and cultural contexts.

Acceptability may be influenced by:

- how the recommendations are translated into policies and actions (e.g. nutrition labelling policies, marketing policies, fiscal policies, reformulation, etc.) because some may be more acceptable than others;
- level of awareness of the health problem that overweight and obesity pose (e.g. it may be less acceptable in settings where awareness is low);
- potential impact on national economies; and
- compatibility with existing policies.

At an individual level, for those who acknowledge the evidence linking total fat intake to unhealthy weight gain and value reducing the risk of unhealthy weight gain, acceptability should be high because overweight and obesity are a significant, recognized global health problem. As noted with respect to feasibility, however, there are many for whom the recommendation will not be acceptable based on the popular perception that high fat diets are healthy, particularly with respect to losing weight or maintaining a healthy body weight (83).

Equity and human rights

The recommendations in this guideline have the potential to reduce health inequity by improving the health of those of lower socioeconomic status because they are generally disproportionately affected by overweight and obesity. However, the effect on equity and human rights will probably be affected by how the recommendations are translated into policies and actions (e.g. fiscal policies and reformulation). The impact of some previously mentioned interventions on the pricing of manufactured foods would require careful consideration, because any increase in costs borne by manufacturers might be passed on to the consumer, which would be likely to disproportionately affect those of lower socioeconomic status.

In addition, a reduction in total fat intake may have different impacts on diets depending on what the nature of the dietary fat is in average diets in different settings. For example, in some settings, dietary fat may consist largely of unsaturated fatty acids and a reduction in total fat intake may have an impact on body weight but not CVDs. In settings where dietary fat consists largely of saturated fatty acids or trans-fatty acids, a reduction in total fat intake may have an impact on both body weight and CVDs. Because saturated fatty acids and trans-fatty acids may make up a larger percentage of total fat intake in some LMICs (84), in those settings reducing total fat intake might result in health benefits both in terms of body weight and cardiovascular health.

Resource implications

Costs of translating the recommendations into polices and actions will vary widely, depending on which approaches are taken, but will probably be associated with long-term savings in costs of health care. The extent of these savings and resource use depends on the strategies chosen for implementation and the timescale for evaluation. Implementation of the recommendations will probably require consumer education and public health communications, some or all of which can be incorporated into existing public health nutrition education campaigns and other existing nutrition programmes at the global, regional, national and subnational levels.
Recommendations and supporting information

These recommendations should be considered in the context of other WHO guidelines on healthy diets, including those on saturated fatty acids and trans-fatty acids (68), polyunsaturated fatty acids (56), sugars (81), carbohydrates (86), non-sugar sweeteners (87), sodium (88) and potassium (89). An explanation of the strength of WHO recommendations can be found in Box 1.

<table>
<thead>
<tr>
<th>WHO recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. To reduce the risk of unhealthy weight gain, WHO suggests that adults limit total fat intake to 30% of total energy intake or less (conditional recommendation).</td>
</tr>
<tr>
<td>2. Fat consumed should be primarily unsaturated fatty acids, with no more than 10% of total energy intake coming from saturated fatty acids and no more than 1% of total energy intake coming from trans-fatty acids (strong recommendation).</td>
</tr>
</tbody>
</table>

Rationale for recommendation 1

▶ This recommendation is based on evidence of high certainty from a systematic review of RCTs of dietary fat reduction in adults in which weight loss was not an explicit goal (13). All measures of body fatness assessed in the review (i.e. body weight, BMI, waist circumference and percentage body fat) were lower in adult participants randomized to a lower fat intake versus usual or moderate intake, with the most commonly reported measure being body weight. The evidence further suggests that the greater the difference in fat intake between those reducing fat intake and those not doing so, the greater the difference in body weight (i.e. a dose–response relationship), regardless of the final level of total fat intake achieved. Overall, the evidence suggests that a lower fat intake has the potential to help reduce the risk of unhealthy weight gain.³

▶ The threshold of 30% was selected because most of the trials included in the analyses reported total fat intakes of 30% or more at baseline (range: 29–43% of total energy intake) and most studies achieved intakes of 30% or less in the intervention arms (range: 14–35% of total energy intake). When compared directly via subgroup analysis, there was a greater difference in body weight in trials where total fat intake was reduced to a final level of less than 30% of total energy intake in the intervention arms than in trials where total fat intake was reduced to a final level that was 30% of total energy intake or more in the intervention arms. In addition, the observed dose–response relationship indicates a cumulative effect of lower fat intake across the range of baseline intakes, with a greater reduction in fat intake resulting in a greater difference in body weight. Therefore, although an effect on body weight is anticipated with reducing total fat intake regardless of the level of total fat intake achieved, the greatest effect may be achieved with a reduction to 30% of total energy intake or less.

---

1 WHO guidance on polyunsaturated fatty acids is currently being updated.
2 The differences in measures of body fatness reported at the end of the individual trials reflect lower body fatness in the lower fat intervention arms compared with the usual or moderate fat intake groups. In some trials, this was due to a smaller increase in body weight over time in the lower fat intervention arms than in the control arms, and in others, body weight decreased in the intervention arms but decreased by less, stayed the same or increased in the control arms.
3 Given the inability to pool the effects of the identified cohort studies via meta-analysis, the qualitative results from the cohort studies being not inconsistent with those from the RCTs, and the data from the RCTs being robust and of higher certainty, the evidence from cohort studies was reviewed, but was not formally assessed for quality using GRADE methodology or directly used in decision-making with respect to formulating the recommendation or assigning strength.
The recommendation was assessed as conditional because some individuals who reduce their fat intake might replace some of the energy from dietary fat with energy from foods that are undesirable from a dietary quality perspective (e.g. free sugars), reducing the net benefit. It is therefore important to consider this recommendation in the context of other WHO dietary recommendations, including those on free sugars (85) and carbohydrates (86), the latter of which provides guidance on carbohydrate quality. The evidence did not suggest any undesirable effects with respect to serum lipids, blood pressure or quality of life from lower total fat intake, but rather of small benefits or no effect (all high certainty evidence, except for quality of life, which was assessed as low certainty evidence). No mitigating factors were identified\(^1\) that would argue against limiting total fat intake to 30% of total energy intake or less.

**Remarks for recommendation 1**

- This recommendation is relevant for individuals aged 20 years or older.
- The goal in developing this guideline was to provide recommendations for both adults and children. However, the evidence was considered insufficient to support the formulation of a recommendation for children owing to the limited number of studies and inconsistent results identified for children (14), and the conclusion that the adult data could not reasonably be extrapolated to children given the unique energy requirements for optimal growth and development throughout childhood and adolescence. Previous expert consultations on dietary fats have concluded that for children aged 6 months and above and adolescents, total fat intakes of up to 35% of total energy are appropriate to meet growth demands without leading to excess energy intake (59).\(^2\)
- The threshold of 30% in this recommendation should not be interpreted as an upper value of intake to be achieved by increasing fat intake among those with nutritionally adequate total fat intakes that are already less than 30% of total energy intake.
- Evaluation of the evidence suggests that the observed effect of reducing total fat intake on measures of body fatness is mediated, at least in part, by dietary behaviours that affect energy balance. In most trials, those who reduced their total fat intake also decreased their total energy intake (even though that was not intended in the trial design), and this led to decreasing weight. This finding suggests that there may be a tendency for those habitually consuming greater amounts of total fat to also consume more energy than needed, resulting in excess energy intake and subsequent weight gain. However, individuals

---

\(^1\) See the section Evidence to recommendations.

\(^2\) Infants should be exclusively breastfed for the first 6 months of life to achieve optimal growth, development and health. Thereafter, to meet their evolving nutritional requirements, infants should receive nutritionally adequate and safe complementary foods, while continuing to breastfeed for up to 2 years or beyond (9, 90).

---
who can maintain energy balance (or otherwise prevent excess energy intake) at higher fat intakes may be able to consume total fat at levels greater than 30% of total energy intake without increasing their risk of unhealthy weight gain.

▶ The scope of this guideline was limited to developing recommendations for the prevention of unhealthy weight gain, not for the management of existing overweight or obesity. Therefore, studies conducted with overweight participants actively pursuing weight loss (i.e. “weight loss studies”) were not included in the systematic review used to inform the recommendation. The recommendation may therefore not apply to individuals actively pursuing weight loss through modification of the diet, although current evidence does suggest that lower fat, restricted-calorie diets may be one of several effective, short-term strategies for losing excess body weight (50, 91).

▶ This recommendation should not be interpreted as implying that total fat is the only risk factor for unhealthy weight gain and that reducing total fat intake alone is sufficient to prevent unhealthy weight gain. The etiology of unhealthy weight gain is complex and can involve many different inputs. Therefore, this recommendation should be considered in the context of other relevant WHO guidance, including that on the intake of free sugars (85), carbohydrates (86), non-sugar sweeteners (87), energy requirements (92) and physical activity (93).

▶ Dietary fat, including essential fatty acids (which cannot be synthesized by the human body), is necessary for proper physiological function. To ensure an adequate intake of energy and essential fatty acids, and to facilitate the absorption of lipid-soluble vitamins, total fat intake in most adults should be at least 15–20% of total energy intake (58).

▶ The decision to implement this recommendation must be made in the context of achieving or maintaining nutritional adequacy and avoiding excess energy intake. In populations where undernutrition is not prevalent, the recommendation can generally be safely implemented as needed, provided that individual energy requirements are met (92), and recognizing that energy requirements are increased in pregnant and lactating women (9, 10, 92). Consideration must be given to populations in which prevalence of undernutrition is a concern and where total fat intake may already be low. In such settings, maintaining or even increasing total fat intake of individuals (in line with guidance on fat quality in recommendation 2) may be important to achieve adequate energy intake, as well as maintain or improve the overall diet.

Rationale for recommendation 2

▶ This recommendation is taken from recommendations found in the WHO guideline, *Saturated fatty acid and trans-fatty acid intake for adults and children* (68) which are based on effects of these nutrients on mortality and CVD outcomes.

Remarks for recommendation 2

▶ This recommendation is relevant for all individuals aged 2 years and older.

▶ This recommendation, taken together with recommendation 1, acknowledges that both quantity and quality of fat consumed are important for health and nutritional well-being.

▶ Further remarks may be found in the WHO guideline, *Saturated fatty acid and trans-fatty acid intake for adults and children* (68).
Uptake of the guideline and future work

**Dissemination**

The guideline will be disseminated through:

- the WHO e-Library of Evidence for Nutrition Actions (eLENA),¹ which is an online library of evidence-informed guidance for nutrition interventions that provides policy-makers, programme managers, health workers, partners, stakeholders and other interested actors with access to the latest nutrition guidelines and recommendations, as well as complementary documents, such as systematic reviews, and biological, behavioural and contextual rationales for the effectiveness of nutrition actions;

- relevant nutrition webpages on the WHO website, including a summary of the guideline in all six official WHO languages;

- the electronic mailing lists of the WHO Department of Nutrition and Food Safety, and the UN Standing Committee on Nutrition;

- the network of the six WHO regional offices and country offices; and

- the WHO collaborating centres.

The guideline will also be disseminated at various relevant WHO meetings, as well as at global and regional scientific meetings.

**Translation and implementation**

These recommendations should be considered in the context of other WHO guidelines on healthy diets — in particular those on saturated fatty acids, *trans*-fatty acids (68), polyunsaturated fatty acids (56),² sugars (85), carbohydrates (86) and non-sugar sweeteners (87), as well as sodium (88) and potassium (89), to guide effective policy actions and intervention programmes to promote healthy diets and nutrition, and prevent obesity and diet-related NCDs.

A detailed discussion of how the recommendations on total fat intake might be implemented is beyond the scope of this guideline, however they can be considered by policy-makers and programme managers when discussing possible measures, including:

- assessing current intake of total fat in their populations relative to a benchmark;

- developing policy measures to reduce intake of total fat, where necessary, through a range of public health interventions, many of which are already being implemented by countries, including:

  - nutrition labelling (i.e. mandatory nutrient declaration) and front-of-pack labelling systems
  - regulation of marketing food and non-alcoholic beverages that are high in total fat, including bans on marketing of food that contains industrially produced *trans*-fat
  - restricting the sales and promotion of food and beverages that are high in total fat in and around schools
  - fiscal policies targeting foods and beverages that are high in total fat
  - consumer education

¹ [https://www.who.int/tools/elena](https://www.who.int/tools/elena)
² WHO guidance on polyunsaturated fatty acids is currently being updated.
developing strategies to reformulate food products; and

translating at the country-level into culturally and contextually specific food-based dietary guidelines that take into account locally available food and dietary customs.

The recommendations in this guideline acknowledge that both quantity and quality of fat consumed are important for maintaining health. Public health interventions should therefore aim to reduce total fat intake where necessary, while reducing saturated fatty acid and trans-fatty acid intake, through replacement with unsaturated fatty acids or carbohydrates as needed (68), and without increasing free sugars intake (85).

Providing overall dietary guidance is outside the scope of this guideline because such guidance should be based on overall dietary goals that consider all required nutrients. However, it is feasible to achieve the recommendations in this guideline while respecting national dietary customs, because a wide variety of fresh foods are naturally low in fat, and reduced fat versions of whole foods such as reduced fat dairy foods and lean cuts of meat are available in many countries. Highly processed foods that are high in fat should be replaced with whole foods where possible, because many highly processed fat-free and low-fat products contain free sugars and may contain as many calories as full-fat versions.

The decision to implement this recommendation must be made in the context of achieving or maintaining nutritional adequacy and avoiding excess energy intake. In populations where undernutrition is not prevalent, the recommendation can generally be safely implemented as needed, provided individual energy requirements are met (92), recognizing that energy requirements are increased in pregnant and lactating women (9, 10, 92). Consideration must be given to populations in which prevalence of undernutrition is a concern and where total fat intake may already be low. In such settings, maintaining or even increasing total fat intake of individuals (in line with guidance on fat quality in recommendation 2) may be important to achieve adequate energy intake, and to maintain or improve the overall diet.

Monitoring and evaluation

The impact of this guideline can be evaluated by assessing its adoption and adaptation across countries that will be monitored in close collaboration with the WHO regional and country offices. Monitoring and evaluation at the global level will be through the WHO Global Database on the Implementation of Nutrition Action (GINA) – a centralized platform developed by the WHO Department of Nutrition and Food Safety for sharing information on nutrition actions in public health practice implemented around the world. GINA currently contains information on thousands of policies (including laws and legislation), nutrition actions and programmes being implemented in WHO Member States. GINA includes data and information from many sources, including the first and second WHO Global Nutrition Policy Reviews conducted in 2010–2011 and 2016–2017, respectively (94, 95). Through providing programmatic implementation details, specific country adaptations and lessons learned, GINA serves as a platform for monitoring and evaluating how guidelines are being translated into various policy actions and intervention programmes to address the issues related to fat intake in various countries.

Research gaps and future initiatives

Based on the results of the systematic reviews and discussions with the NUGAG Subgroup on Diet and Health, a number of questions and gaps in the current evidence that should be addressed by future research were identified, as outlined below. Research needs include high-quality studies that assess the:

- effects of reducing total fat intake or otherwise lower fat intakes on body fatness and other metabolic markers, in particular in LMICs;
- associations between changes in body fatness and increased total fat intake in diverse populations in LMICs with low but nutritionally adequate total fat intakes (e.g. cohort studies in populations undergoing the nutrition transition);
- effects of reducing total fat intake or otherwise lower fat intakes on relevant health outcomes in addition to body fatness (e.g. mortality, CVDs and cancer), noting that in some populations, the relationship between measures of body fatness and health risks may differ.

1 https://extranet.who.int/nutrition/gina/en/home
effects of diets that vary in addition to total fat intake, using detailed dietary data, to determine whether background diet affects the relationship between total fat intake and body fatness;

- effects on body weight of altering total fat intake in children;
- long-term health effects of high fat diets; and
- possible physiological mechanisms for observed association between total fat intake and body weight.

**Updating the guideline**

WHO regularly updates its guidelines and recommendations to reflect the latest scientific and medical knowledge. This guideline will therefore be updated as part of the ongoing efforts of WHO to update existing dietary goals and nutrition guidance for promoting healthy diets, nutrition and the prevention of NCDs. It is planned that the recommendations in this guideline will be reviewed when new data and information become available. At that time, any new evidence will be evaluated, and formal updates will be made, if necessary. The WHO Department of Nutrition and Food Safety, together with partners in other departments within the WHO Secretariat, will be responsible for coordinating the updating of the guideline, following the formal procedure described in the WHO handbook for guideline development (60). At the time the guideline is due for review, WHO will welcome suggestions for additional questions that could be addressed in a potential update of the guideline.

Uptake of the guideline and future work
References


27.

References


Annexes
Annex 1
Members of the WHO Steering Group

**Dr Ayoub Al-Jawaldeh**  
Regional Adviser in Nutrition  
WHO Regional Office for the Eastern Mediterranean  
Egypt

**Dr Hana Bekele**  
Nutrition Adviser  
WHO Regional Office for Africa/Intercountry Support Team for East and Southern Africa (IST/ESA)  
Congo

**Dr Fabio Da Silva Gomes**  
Nutrition and Physical Activity Adviser  
WHO Regional Office for the Americas  
United States of America

**Dr Padmini Angela De Silva**  
Regional Adviser in Nutrition  
WHO Regional Office for South-East Asia  
India

**Dr Jason Montez**  
Scientist, Standards and Scientific Advice on Food and Nutrition  
Department of Nutrition and Food Safety  
WHO headquarters  
Switzerland

**Dr Chizuru Nishida**  
Unit Head, Safe, Healthy and Sustainable Diet  
Department of Nutrition and Food Safety  
WHO headquarters  
Switzerland

**Dr Juan Pablo Peña-Rosas**  
Unit Head, Global Initiatives  
Department of Nutrition and Food Safety  
WHO headquarters  
Switzerland

**Dr Juliawati Untoro**  
Regional Adviser in Nutrition  
WHO Regional Office for the Western Pacific  
Philippines

**Dr Cherian Varghese**  
Cross Cutting Lead for NCD and Special Initiatives  
Department of Noncommunicable Diseases  
WHO headquarters  
Switzerland

**Dr Kremlin Wickramasinghe**  
Nutrition Adviser  
WHO European Office for the Prevention and Control of NCDs  
Russian Federation

**Dr Ayoub Al-Jawaldeh**  
Regional Adviser in Nutrition  
WHO Regional Office for the Eastern Mediterranean  
Egypt

**Dr Hana Bekele**  
Nutrition Adviser  
WHO Regional Office for Africa/Intercountry Support Team for East and Southern Africa (IST/ESA)  
Congo

**Dr Fabio Da Silva Gomes**  
Nutrition and Physical Activity Adviser  
WHO Regional Office for the Americas  
United States of America

**Dr Padmini Angela De Silva**  
Regional Adviser in Nutrition  
WHO Regional Office for South-East Asia  
India

**Dr Jason Montez**  
Scientist, Standards and Scientific Advice on Food and Nutrition  
Department of Nutrition and Food Safety  
WHO headquarters  
Switzerland

**Dr Chizuru Nishida**  
Unit Head, Safe, Healthy and Sustainable Diet  
Department of Nutrition and Food Safety  
WHO headquarters  
Switzerland

**Dr Juan Pablo Peña-Rosas**  
Unit Head, Global Initiatives  
Department of Nutrition and Food Safety  
WHO headquarters  
Switzerland

**Dr Juliawati Untoro**  
Regional Adviser in Nutrition  
WHO Regional Office for the Western Pacific  
Philippines

**Dr Cherian Varghese**  
Cross Cutting Lead for NCD and Special Initiatives  
Department of Noncommunicable Diseases  
WHO headquarters  
Switzerland

**Dr Kremlin Wickramasinghe**  
Nutrition Adviser  
WHO European Office for the Prevention and Control of NCDs  
Russian Federation
Annex 2
Members of the guideline development group (NUGAG Subgroup on Diet and Health)

**Professor Hayder Al-Domi**
Division of Nutrition and Dietetics
Department of Nutrition and Food Technology
School of Agriculture
University of Jordan
Jordan
Areas of expertise: dietetics, human nutrition, diet and health, obesity biomarkers, diabetogenic dietary proteins

**Professor John H Cummings** (member until 2018)
Division of Cancer Research, Medical Research Institute
Ninewells Hospital & Medical School
University of Dundee
United Kingdom of Great Britain and Northern Ireland
Areas of expertise: carbohydrates, dietary fibre

**Emeritus Professor Ibrahim Elmadfa**
Department of Nutritional Sciences
Faculty of Life Sciences
University of Vienna
Austria
Areas of expertise: human nutrition, nutrient requirements, fats and fatty acids, diet and health, dietary diversity

**Dr Lee Hooper**
Norwich Medical School
University of East Anglia
United Kingdom of Great Britain and Northern Ireland
Areas of expertise: systematic review and research methods, dietetics, human nutrition, hydration, frail older adults and long-term care

**Emeritus Professor Shiriki Kumanyika**
(Chairperson)
Perelman School of Medicine
University of Pennsylvania
United States of America
Areas of expertise: human nutrition, epidemiology, obesity, salt/sodium

**Professor Mary L'Abbé**
Department of Nutritional Sciences
Temerty Faculty of Medicine
University of Toronto
Canada
Areas of expertise: nutrition science, trans-fatty acids, sodium, risk assessment/risk management, food regulation, diet and health

**Professor Pulani Lanerolle**
Department of Biochemistry and Molecular Biology
Faculty of Medicine
University of Colombo
Sri Lanka
Areas of expertise: nutrition and health, body composition, nutrition education

**Professor Duo Li**
Institute of Nutrition & Health
Qingdao University
Department of Food Science and Nutrition
Zhejiang University
China
Areas of expertise: nutritional epidemiology, fats and fatty acids

**Professor Jim Mann**
Departments of Medicine and Human Nutrition
University of Otago
New Zealand
Areas of expertise: carbohydrates, sugars, diabetes, fats and fatty acids

**Professor Joerg Meerpohl**
Institute for Evidence in Medicine
Medical Center, University of Freiburg
Germany
Areas of expertise: systematic review methods, GRADE methodology, paediatrics, paediatric haematology and oncology
Annex 2. Members of the guideline development group

**Professor Carlos Monteiro**
Department of Nutrition, School of Public Health  
University of Sao Paulo  
Brazil  
Areas of expertise: nutritional epidemiology, diet and all forms of malnutrition, obesity, food-based dietary guidelines

**Dr Laetitia Ouedraogo Nikièma** (member until 2020)  
Institut de Recherche en Sciences de la Santé  
Burkina Faso  
Areas of expertise: nutritional epidemiology, maternal and child health and nutrition, all forms of malnutrition, diet-related noncommunicable diseases

**Professor Harshpal Singh Sachdev**  
Sitaram Bhartia Institute of Science and Research  
India  
Areas of expertise: developmental origins of adult cardiometabolic disease, nutrition in children and mothers in low- and middle-income countries, childhood obesity, systematic review methods

**Professor HH (Esté) Vorster** (member until 2020)  
Faculty of Health Sciences  
North-West University  
South Africa  
Areas of expertise: nutrition physiology, public health nutrition, food-based dietary guidelines, nutrition transition in Africa

**Emeritus Professor Murray Skeaff**
Department of Human Nutrition  
University of Otago  
New Zealand  
Areas of expertise: fats and fatty acids, biomarkers, diet and health, human nutrition

**Professor Bruno Fokas Sunguya**
School of Public Health and Social Sciences  
Muhimbili University of Health and Allied Sciences  
United Republic of Tanzania  
Areas of expertise: public health nutrition, research methods, systematic review methodology, human nutrition, nutrition epidemiology

**Dr Barbara Schneeman**
Departments of Nutrition/Food Science and Technology  
University of California, Davis  
United States of America  
Areas of expertise: carbohydrates, dietary fibre, nutrition, diet and health, Codex Alimentarius, food regulation
Annex 3
Members of the external peer review group

Professor Hassan Aguenaou
Director
Ibn Tofail University-CNESTEN
Joint Research Unit in Nutrition, Health and Environment, RDC-Nutrition AFRA/IAEA
Morocco

Professor Anna Lartey
Professor of Nutrition
University of Ghana
Ghana

Professor K. Srinath Reddy
President, Public Health Foundation of India
Gurugram, Haryana
India

Professor Leanne Hodson
Professor of Metabolic Physiology, BHF Senior Research Fellow in Basic Science, Senior Research Fellow Green Templeton College
Oxford Centre for Diabetes, Endocrinology and Metabolism
University of Oxford
United Kingdom of Great Britain and Northern Ireland

Professor Tatsuya Koyama
Assistant Professor of Health Sciences, Department of Nutrition
Aomori University of Health and Welfare
Japan

Dr Juan Rivera Dommarco
Ex-General Director and Senior Professor and Investigator
Instituto Nacional de Salud Pública
Mexico

Professor Linda Snetselaar
Professor and Chair, Preventive Nutrition Education, Director, Nutrition Center
Department of Epidemiology
University of Iowa College of Public Health
United States of America
## Annex 4

### Summary and management of declarations of interests

**Members of the guideline development group (NUGAG Subgroup on Diet and Health)**

Interests declared or otherwise identified independently for the following members during the development of this guideline are summarized below.

<table>
<thead>
<tr>
<th>Member</th>
<th>Interests declared/identified</th>
<th>Action taken</th>
</tr>
</thead>
</table>
| Mary L'Abbé     | ▶ Iodine Global Network: member, Board of Directors (2020–2021)  
▶ PAHO: member/Chair of PAHO consultation meetings for setting sodium reduction targets, and other sodium-related work (2012–2021)  
▶ World Obesity, World Federation of Public Health Associations: delegate representative to Codex Committee on Nutrition and Foods for Special Dietary Uses, and to Codex Committee on Food Labelling (2018–2021)  
▶ National Nutrient Databank Conference: Steering Committee member (2017–2021)  
▶ Nestle Nutrition: external peer reviewer for two research proposals; attended peer review meeting (2018)  
▶ Marketing to Kids Coalition: member and technical adviser, Health Canada discussion on policy options regarding marketing to children (2016–2021) | Each engagement was assessed in the context of the topic of this guideline. While meeting expenses were often covered by the relevant agencies listed, no income or honorariums were paid. The engagements have been on a variety of nutrition topics, none of which were determined to be directly relevant to the objective of this guideline, and were therefore not considered to represent a conflict of interest. The sources of research funds were not considered to represent a conflict of interest for this guideline. Nor were the topics covered by the research funds which focused primarily on assessing dietary quality, ways of promoting healthy diets (including sodium reduction strategies), and food labelling. Because none of the interests were directly relevant to the objective of this guideline, it was determined that they would not impact the ability of this expert to serve as a member of the NUGAG Subgroup |
<table>
<thead>
<tr>
<th>Member</th>
<th>Interests declared/identified</th>
<th>Action taken</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Statistics Canada and Health Canada: technical adviser on analysis of dietary intake patterns for 2015 Canadian Community Health Survey (2015–2021)</td>
<td>on Diet and Health in an objective manner, and the expert was allowed to participate fully as a member of the NUGAG Subgroup on Diet and Health throughout the guideline development process.</td>
</tr>
<tr>
<td></td>
<td>Received research funding from various agencies: Canadian Institute of Health Research, Institute for the Advancement of Food and Nutrition Sciences, Alberta Innovates and Alberta Health Services, Health Canada, Sanofi-Pasteur – University of Toronto – Université Paris – Descartes International Collaborative Research Pilot and Feasibility Program, International Development Research Centre – NCD Prevention Program, Burroughs Wellcome Foundation, Fonds de recherche Société et culture Québec, Heart and Stroke Foundation of Canada (2012–2021)</td>
<td></td>
</tr>
<tr>
<td>Barbara Schneeman</td>
<td></td>
<td>Each engagement was assessed in the context of the topic of this guideline. Meeting expenses and honorariums were paid in some instances. With the exception of membership on the US Dietary Guidelines Advisory Committee, the engagements have all been on topics unrelated to the objective of this guideline, primarily providing expert advice on US regulatory issues, such as food labelling (i.e. nutrient declarations, health claims, other types of labelling), or presenting the process for developing the dietary guidelines for the US, Dietary Guidelines for Americans. Regarding her membership on the US Dietary Guidelines Advisory Committee, although the nature of the work was similar to the work being carried out for this guideline, the work was done for</td>
</tr>
<tr>
<td></td>
<td>US Agency for International Development (USAID): employed as higher education coordinator from 2015 to 2016, where she worked with the higher education community to increase engagement with USAID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>US Food and Drug Administration (FDA): employed through 2012 (retired in 2013)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Head of the US delegate to the Codex Committee on Nutrition and Foods for Special Dietary Uses, and Codex Committee on Food Labelling; she presented the positions of the United States in these Codex forums (up to 2012)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monsanto: member of advisory committee discussing role of agriculture in addressing climate change, and improving food and nutrition security (2014–2017)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>McCormick Science Institute: member of advisory committee reviewing research proposals on spices and herbs (2014–2021)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ocean Spray: temporary adviser on health claim petitions that are submitted to US FDA related to cranberries (2014–2015)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hampton Creek: temporary adviser on labelling standards for mayonnaise (2014–2015)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NASEM: member of the National Academies and member/Chair of the Dietary Guidelines Advisory Committee, involved in reviewing the evidence for developing the Dietary Guidelines for Americans</td>
<td></td>
</tr>
<tr>
<td>Member</td>
<td>Interests declared/identified</td>
<td>Action taken</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>— Nominated to the Dietary Guidelines Advisory Committee of the USA by representatives from the North American Branch of the International Life Sciences Institute; American Beverage Association; American Bakers Association, Grain Chain; Grocery Manufacturers Association USA Dry Pea &amp; Lentil Council, American Pulse Association</td>
<td>a national authority and therefore was not considered a conflict of interest. With respect to her nomination to the US Dietary Guidelines Advisory Committee by various industry groups, there is no relationship or affiliation between nominator and nominee. Because none of the interests were directly relevant to the objective of this guideline or were otherwise determined not to represent a conflict of interest, it was concluded that the interests would not impact the ability of this expert to serve as a member of the NUGAG Subgroup on Diet and Health in an objective manner. The expert was allowed to participate fully as a member of the NUGAG Subgroup on Diet and Health throughout the guideline development process.</td>
</tr>
<tr>
<td></td>
<td>— Received honorariums for presentations on the process to develop the Dietary Guidelines for Americans and policies for food labelling in the United States at various scientific meetings organized by PMK Associates (Institute of Food Technologists and American Oil Chemists’ Society), McCormick Science Institute, Fiber Association Japan, and Mushroom Council</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ International Food Information Council (IFIC): member, Board of Trustees, which ensures that IFIC upholds its responsibilities as a 501(c)(3) non-profit organization (2021)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ International Dairy Foods Association: presented webinar on the work of the 2020 Dietary Guideline Advisory Committee, for which she received no remuneration (2020)</td>
<td></td>
</tr>
</tbody>
</table>

No other members of the NUGAG Subgroup on Diet and Health declared any interests (or the declared interests clearly did not represent a conflict of interest), nor were any interests independently identified (see Annex 2 for the list of members of the NUGAG Subgroup on Diet and Health).

**Members of the external peer review group**

No members of the external peer review group declared any interests, nor were any interests independently identified (see Annex 3 for the full list of external peer reviewers).

**Members of the systematic review teams**

No members of the systematic review teams declared any interests, nor were any interests independently identified.
### Annex 5

**Key question in PICO format (population, intervention, comparator, outcome)**

What is the effect of reduced intake of total fat on measures of body fatness in adults and children?

| **Population** | Apparently healthy adults or children in low-, middle- and high-income countries  
| >> In each, consider population characteristics, such as age, sex, ethnicity, country/region (urban/rural), socioeconomic status/demographic factors/sanitation health background and health status |
| **Intervention/exposure** | Total dietary fat/dietary fatty acids  
| >> % energy intake from total fat |
| **Control** | Comparison of levels  
| >> Continuous or categorical  
| >> Appropriately matched to intervention group by randomization |
| **Major confounders/effect modifiers/intermediates** | Baseline level of total fat intake  
| >> Energy intake  
| >> Energy expenditure; fitness and physical activity  
| >> Consider other interventions in design, dietary and non-dietary  
| >> Consider influence of other aspects of diet/dietary patterns  
| **Intermediates** | Take into account effect of energy density |
| **Outcome** | Unhealthy weight gain as assessed by measures of body fatness (e.g. body weight, body mass index, waist circumference, skinfold thickness, percentage body fat) |
| **Time frame** | For randomized controlled trials, minimum study duration is 6 months  
| >> For prospective cohort studies, minimum of 12 months of follow-up |
## Annex 6
### GRADE evidence profiles

#### GRADE evidence profile 1

**Question:** What is the effect of a reduction in total fat intake in adults?\(^1\)

**Population:** General adult population

<table>
<thead>
<tr>
<th>Variable</th>
<th>Assessment</th>
<th>No. of studies</th>
<th>Design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other</th>
<th>Reduced fat intake</th>
<th>Usual fat intake</th>
<th>Relative effect (95% CI)</th>
<th>Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (kg)</td>
<td></td>
<td>26 (3)</td>
<td>RCT</td>
<td>Not serious(^3)</td>
<td>Not serious(^4)</td>
<td>Not serious(^5)</td>
<td>Not serious(^6)</td>
<td>None(^7)</td>
<td>22 397</td>
<td>31 478</td>
<td>MD –1.42 (–1.73 to –1.10)</td>
<td>HIGH</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td></td>
<td>14 (17)</td>
<td>RCT</td>
<td>Not serious(^8)</td>
<td>Not serious(^9)</td>
<td>Not serious(^8)</td>
<td>Not serious(^9)</td>
<td>None(^7)</td>
<td>18 891</td>
<td>27 648</td>
<td>MD –0.47 (–0.64 to –0.30)</td>
<td>HIGH</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td></td>
<td>3 (6)</td>
<td>RCT</td>
<td>Not serious(^10)</td>
<td>Not serious(^11)</td>
<td>Not serious(^8)</td>
<td>Not serious(^9)</td>
<td>None(^7)</td>
<td>6 570</td>
<td>10 050</td>
<td>MD –0.4 (–0.73 to –0.22)</td>
<td>HIGH</td>
</tr>
<tr>
<td>Percentage body fat (%)</td>
<td></td>
<td>2 (2)</td>
<td>RCT</td>
<td>Not serious(^12)</td>
<td>Not serious(^13)</td>
<td>Not serious(^14)</td>
<td>Not serious(^15)</td>
<td>None(^7)</td>
<td>926</td>
<td>1 424</td>
<td>MD –0.28 (–0.57 to 0.00)</td>
<td>MODERATE</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td></td>
<td>22 (27)</td>
<td>RCT</td>
<td>Not serious(^16)</td>
<td>Not serious(^17)</td>
<td>Not serious(^8)</td>
<td>Not serious(^9)</td>
<td>None(^16)</td>
<td>4 604</td>
<td>5 208</td>
<td>MD –0.23 (–0.32 to –0.14)</td>
<td>HIGH</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td></td>
<td>19 (22)</td>
<td>RCT</td>
<td>Not serious(^16)</td>
<td>Not serious(^13)</td>
<td>Not serious(^8)</td>
<td>Not serious(^9)</td>
<td>None(^16)</td>
<td>3 781</td>
<td>4 356</td>
<td>MD –0.13 (–0.21 to –0.09)</td>
<td>HIGH</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td></td>
<td>20 (24)</td>
<td>RCT</td>
<td>Not serious(^16)</td>
<td>Not serious(^10)</td>
<td>Not serious(^8)</td>
<td>Not serious(^9)</td>
<td>None(^16)</td>
<td>3 841</td>
<td>4 427</td>
<td>MD –0.02 (–0.03 to 0.00)</td>
<td>HIGH</td>
</tr>
<tr>
<td>Assessment</td>
<td>No. of participants</td>
<td>Relative effect</td>
<td>Confidence interval</td>
<td>Certainty</td>
<td>Risk of bias</td>
<td>Indirectness</td>
<td>Imprecision</td>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------</td>
<td>-------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol/HDL cholesterol ratio (unitless)</td>
<td>5 (8)</td>
<td></td>
<td>0.05</td>
<td>-0.14 to 0.04</td>
<td>HIGH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>17 (22)</td>
<td></td>
<td>MD -0.05</td>
<td>-0.14 to 0.04</td>
<td>HIGH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>10 (13)</td>
<td></td>
<td>MD -0.75</td>
<td>-1.42 to -0.07</td>
<td>HIGH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>10 (13)</td>
<td></td>
<td>MD -0.52</td>
<td>-0.55 to -0.09</td>
<td>HIGH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life (scale of 0–10 with 10 being highest)</td>
<td>1 (1)</td>
<td></td>
<td>MD 0.04</td>
<td>0.01 to 0.07</td>
<td>HIGH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BMI: body mass index; CI: confidence interval; HDL: high density lipoprotein; LDL: low density lipoprotein; MD: mean difference; RCT: randomized controlled trial.

1. RCTs included in the meta-analysis reported baseline total fat intakes of 29–43% of total energy intake and reductions in body weight were observed across all baseline values, with most RCTs having baseline intakes of 30% or greater. In the published systematic review, all measures of body fatness were grouped together for GRADE assessment and assigned a collective rating of high. For this guideline the measures of body fatness were assessed individually, and all outcomes except body fat percentage were assigned a rating of high (body fat percentage was assigned a rating of moderate).

2. Number of comparisons provided in parentheses.

3. Most of the studies included in the meta-analysis (18 out of 26) appeared to use appropriate methods of random sequence generation and allocation concealment. However, issues with compliance were not an important source of bias, and systematic differences in attrition, loss to follow-up, and 2-week diet intervention adherence were not significant. The heterogeneity was partly explained by the degree of reduction of fat intake, BMI of participants, and the level of dietary intervention adherence in these RCTs. A high level of interaction was noted with studies that used more focused interventions (on top of the change in dietary fats), studies with high compliance, and studies that delivered additional dietary interventions (e.g., monthly follow-up visits or newsletters). The effect of these factors was not significant on body weight, but it was significant on other outcomes (e.g., quality of life and cardiovascular risk factors).

4. I² = 75%, indicating a significant level of heterogeneity. The heterogeneity was partly explained by the degree of reduction of fat intake, BMI of participants, and the level of dietary intervention adherence in these RCTs. A high level of interaction was noted with studies that used more focused interventions (on top of the change in dietary fats), studies with high compliance, and studies that delivered additional dietary interventions (e.g., monthly follow-up visits or newsletters). The effect of these factors was not significant on body weight, but it was significant on other outcomes (e.g., quality of life and cardiovascular risk factors).

5. I² = 10%, indicating a low level of heterogeneity. The heterogeneity was partly explained by the degree of reduction of fat intake, BMI of participants, and the level of dietary intervention adherence in these RCTs. A high level of interaction was noted with studies that used more focused interventions (on top of the change in dietary fats), studies with high compliance, and studies that delivered additional dietary interventions (e.g., monthly follow-up visits or newsletters). The effect of these factors was not significant on body weight, but it was significant on other outcomes (e.g., quality of life and cardiovascular risk factors).
All included RCTs directly compared (and randomized participants) to lower versus usual fat intake. Participants were directly relevant because they came from all parts of the world, included men and women, and people who were healthy, with risk factors or with long-term conditions at baseline. The studies all addressed measures of body fatness or potential undesirable effects directly and did not use proxy measures.

Large numbers of participants (a minimum of approximately 2400, and for most outcomes many more) were included in RCTs of at least 6 months duration. The 95% CI does not cross a threshold of irrelevant benefit or important harm.

The funnel plot did not suggest publication bias. The consistent reduction in body weight observed, despite the fact that none of the studies included intended to alter weight in either arm, suggests that publication bias for this outcome is unlikely.

Most of the studies included in the meta-analysis (12 of 14) appeared to use appropriate methods of random sequence generation although most did not have clear reporting on allocation concealment. None of the studies were blinded; however, blinding in dietary trials is generally very difficult with the exception of a small number of trials that provide foods in which macronutrients have been covertly modified. It was not clear in most studies whether blinding of outcome assessment had been achieved. Incomplete outcome reporting was variable across studies, with many having a high risk of attrition bias as defined in this analysis (studies that lost more than 5% of participants per year were considered to be at high risk of attrition bias), though selective reporting was assessed as probably not having a significant impact on risk of bias. Most included studies had systematic differences in care (i.e. intervention arms had more time or attention devoted to them than the control arm); however, sensitivity analysis conducted for body weight (which has many studies in common with those reporting BMI) in which studies with systematic differences in care were excluded did not significantly change the effect observed on body weight, suggesting that systematic differences in care were not an important source of bias in these studies. Most studies did not suggest bias resulting from variable compliance, and sensitivity analysis conducted for body weight (which has many studies in common with those reporting BMI) in which studies with suspected problems with compliance were excluded did not significantly change the effect observed on body weight, suggesting that issues with compliance were not an important source of bias in these studies. No other significant biases were noted.

I² = 60%, indicating a moderate level of heterogeneity. The only inconsistency (where heterogeneity arose) was in the size of this effect. Otherwise, the direction of effects in these RCTs was remarkably consistent – 15 of the 17 comparisons showed a decrease in body weight. The reduction in BMI in those on reduced fat diets was seen in different populations and from 6 months to several years. Effects on BMI are supported by similar numbers on body weight, waist circumference and percentage of body fat. Therefore, although formal analysis indicated a moderate level of heterogeneity, additional evidence indicated that the effect was robust and consistent across a large number of studies and was therefore not downgraded.

Both studies included in the meta-analysis appeared to use appropriate methods of random sequence generation and no significant issues with incomplete outcome data, or selective reporting, but neither was free from systematic differences in care. One study did not report sufficient information to make an assessment on allocation concealment, blinding of outcome assessment or compliance. No other significant biases were noted.

I² = 21%, indicating a low level of heterogeneity.

All three studies included in the meta-analysis appeared to use appropriate methods of random sequence generation and had good allocation concealment and no significant issues with blinding of outcome assessment, incomplete outcome data, selective reporting or compliance. One study was not free from systematic differences in care. No other significant biases were noted.

I² = 0%, indicating no heterogeneity.

Of the two studies reporting percentage body fat, one (1) carried 98.8% of the weight in meta-analysis and therefore contributed virtually all the data. This study was conducted in postmenopausal women from different ethnic backgrounds living in the United States of America. Although the effect observed for percentage body fat in this population was consistent with the effects observed for body weight, BMI and waist circumference in larger, more heterogeneous populations, there was no evidence to indicate that the physiological response to a change in total fat intake would be significantly different between this group and the general adult population, this outcome has been downgraded for indirectness as a conservative measure.

Although a small, clinically insignificant effect was observed and the 95% CI crosses the null, it does not cross a threshold of important benefit or harm. Taken together, this was considered as precise evidence of no effect and therefore not downgraded.

Most of the studies included in these meta-analyses appeared to use appropriate methods of random sequence generation but many did not provide sufficient information to assess allocation concealment. None of the studies were blinded; however, blinding in dietary trials is generally very difficult with the exception of a small number of trials that provide foods in which macronutrients have been covertly modified. It was not clear in most studies whether blinding of outcome assessment had been achieved. Incomplete outcome reporting was variable across studies, with many having a high risk of attrition bias as defined in this analysis (studies that lost more than 5% of participants per year were considered to be at high risk of attrition bias), although selective reporting was assessed as probably not having a significant impact on risk of bias. Most included studies had systematic differences in care (i.e. intervention arms had more time or attention devoted to them than the control arm); however, sensitivity analysis conducted for body weight (which has many studies in common with those reporting on blood lipids) in which studies with systematic differences in care were excluded did not significantly change the effect observed on body weight, suggesting that systematic differences in care were not an important source of bias in these studies. Most studies did not suggest bias resulting from variable compliance, and sensitivity analysis conducted for body weight (which has many studies in common with those reporting on blood lipids) in which studies with suspected problems with compliance were excluded, did not significantly change the effect observed on body weight, suggesting that issues with compliance were not an important source of bias in these studies. No other significant biases were noted.
Total fat intake for the prevention of unhealthy weight gain in adults and children: WHO guideline

The only inconsistency (where heterogeneity arose) was in the size of this effect. Otherwise, the direction of effects in these RCTs was remarkably consistent – 22 of the 27 comparisons showed a decrease in total cholesterol. The reduction in total cholesterol in those on reduced fat diets was seen in different populations and from 6 months to several years. Therefore, although formal analysis indicated a moderate level of heterogeneity, additional evidence indicated that the effect was robust and consistent across a large number of studies and was therefore not downgraded.

The funnel plots were difficult to interpret but did not suggest publication bias.

Most of the studies included in the meta-analysis (4 of 5) appeared to use appropriate methods of random sequence generation and three of them had good allocation concealment. None of the studies were blinded; however, blinding of dietary trials is generally very difficult with the exception of a small number of trials that provide foods in which macronutrients have been covertly modified. Blinding of outcome assessment was achieved in one study and the others did not provide sufficient information to assess. About half the studies did not report issues with incomplete outcome data, selective reporting or systematic differences in care. All but one reported good compliance. No other significant biases were noted.

This single, large and well-conducted study appeared to use appropriate methods of random sequence generation, had good allocation concealment and no issues with binding of outcome assessment, incomplete data, selective reporting or compliance. This study did have systematic differences in care. No other significant biases noted.

This study included more than 40,000 participants with several years of follow-up. The 95% CI does not cross a threshold of irrelevant benefit or important harm.
## GRADE evidence profile 2

**Question:** What is the effect of a reduction in total fat intake in children?  

**Population:** General child population

<table>
<thead>
<tr>
<th>Assessment</th>
<th>No. of studies</th>
<th>Design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other</th>
<th>Reduced fat intake</th>
<th>Usual fat intake</th>
<th>Relative effect (95% CI)</th>
<th>Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI: follow-up 1 year (kg/m²)</td>
<td>1</td>
<td>RCT</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious²</td>
<td>None</td>
<td>96</td>
<td>93</td>
<td>MD -1.5 lower (-2.45 to -0.55)</td>
<td>MODERATE</td>
<td></td>
</tr>
<tr>
<td>BMI: follow-up 3 years (kg/m²)</td>
<td>1</td>
<td>RCT</td>
<td>Not serious³</td>
<td>Not serious</td>
<td>Serious⁴</td>
<td>Serious⁵</td>
<td>None</td>
<td>293</td>
<td>283</td>
<td>MD 0.00 (-0.63 to 0.63)</td>
<td>LOW</td>
</tr>
<tr>
<td>Weight: follow-up 3 years (kg)</td>
<td>1</td>
<td>RCT</td>
<td>Not serious³</td>
<td>Not serious</td>
<td>Serious⁴⁵¹²</td>
<td>Serious⁵</td>
<td>None</td>
<td>314</td>
<td>298</td>
<td>MD -0.60 lower (-2.39 to 1.19)</td>
<td>LOW</td>
</tr>
<tr>
<td>Weight-for-age-z-score: follow-up 1 year (unitless)</td>
<td>1</td>
<td>RCT</td>
<td>Serious⁴³</td>
<td>Not serious</td>
<td>Serious⁴⁵¹²</td>
<td>Serious⁵</td>
<td>None</td>
<td>73</td>
<td>76</td>
<td>MD -0.18 lower (-0.51 to 0.15)</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

BMI, body mass index; CI: confidence interval; MD: mean difference; RCT: randomized controlled trial.

1. Baseline intakes of total fat were 30% of total energy intake or higher in the RCTs conducted in children, and the goal of the intervention was to reach intakes of less than 30% of total energy intake.
2. Only single trials were undertaken for each outcome so it was not possible to assess inconsistency.
3. There were too few studies to formally assess publication bias.
4. This study was downgraded once for serious risk of bias because it was unclear whether allocation concealment was achieved.
5. The study was conducted in the population of interest and assessed the effect of reduced total fat intake on the priority health outcome decided on before initiating review.
6. The 95% CI did not cross a threshold of irrelevant benefit or important harm.
7. Additional evidence on the relationship between reduced total fat intake and measures of body fatness in children comes from additional follow-up data of effects on BMI in this study at 1 year (MD -0.30 kg/m²; 95% CI -0.75, 0.15; 620 participants; low certainty in the evidence) and approximately 7 years (MD -0.10 kg/m²; 95% CI -0.75, 0.55; 576 participants; low certainty in the evidence). The last measurements in this study were made on a final visit of the children, which was at approximately 7 years after initiation of the study for many participants. The variability in the actual time of follow-up as well as attenuation of the intervention after 3 years of follow-up decreased confidence in the data for the final follow-up period. The data for the final visit is consistent with the data at both 1 year and 3 years of follow-up, in that no significant effect was observed at any timepoint.
8. This was a well-conducted RCT with methods in place to minimize risk of selection, performance, detection, attrition and reporting bias.
9. Downgraded once for serious indirectness: participants were children with raised blood lipids, and therefore results may not be directly generalizable to all children.
10. The 95% CI crosses a threshold of potentially relevant benefit or important harm.
11. Additional evidence on the relationship between reduced total fat intake and measures of body fatness in children comes from additional follow-up data of effects on body weight in this study at 1 year (MD -0.50 kg/m²; 95% CI -1.78, 0.78; 620 participants; low certainty in the evidence)
Weight and weight-for-age z-scores may not be sufficiently indicative of changes in body fatness because these measures do not factor in changes and differences in height, which are known to vary greatly across children throughout development. Already downgraded for indirectness.

Unclear risk of bias across all domains.

References for Annex 6

Annex 7
Evidence to recommendations table

Background

**Intervention:** reduced total fat intake  
**Comparison:** usual diet  
**Main outcomes:** measures of body fatness  
**Setting:** healthy individuals; randomized controlled trials

Assessment

<table>
<thead>
<tr>
<th>Judgement</th>
<th>Research evidence</th>
<th>Additional considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Is the problem a priority?</strong></td>
<td>In 2016, more than 1.9 billion adults aged 18 years and older were overweight (1). Of these, more than 600 million were obese. In 2020, more than 38 million children under 5 years of age were overweight – an increase of nearly 6 million since 2000 (2). High body mass index (BMI) was responsible for an estimated 4 million deaths in 2015 (3), with greater increases in BMI in the overweight and obesity range leading to a greater risk of mortality (4). Overweight and obesity are also risk factors for many noncommunicable diseases (NCDs) including cardiovascular diseases (CVDs), type 2 diabetes and certain types of cancers. NCDs are the leading causes of death globally and were responsible for an estimated 41 million (71%) of the 55 million deaths in 2019 (5).</td>
<td>Rates of obesity and diet-related NCDs are growing rapidly in LMICs.</td>
</tr>
<tr>
<td>☐ No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Probably no</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Probably yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>■ Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Don’t know</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **How substantial are the desirable anticipated effects?** | The desirable effects of reducing total fat intake are as follows:  
Body weight: Mean difference (MD) –1.42 kg (95% CI: –1.73, –1.10)  
Body mass index: MD –0.47 kg/m² (95% CI: –0.64, –0.30)  
Waist circumference: MD –0.47 cm (95% CI: –0.73, –0.22)  
Percentage of body fat: MD –0.28% (95% CI: –0.57, 0.00)  
The primary effect on body weight was considered to be small and the other effects small to trivial. |                                                                                          |
| ☐ Trivial                     |                                                                                                                                                                                                                 |                                                                                          |
| ■ Small                       |                                                                                                                                                                                                                 |                                                                                          |
| ☐ Moderate                    |                                                                                                                                                                                                                 |                                                                                          |
| ☐ Large                       |                                                                                                                                                                                                                 |                                                                                          |
| ☐ Varies                      |                                                                                                                                                                                                                 |                                                                                          |
| ☐ Don’t know                  |                                                                                                                                                                                                                 |                                                                                          |
### Undesirable Effects

<table>
<thead>
<tr>
<th>Judgement</th>
<th>Research evidence</th>
<th>Additional considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How substantial are the undesirable anticipated effects?</strong></td>
<td>There were no identified adverse effects of any kind associated with reducing total fat intake. A number of outcomes were assessed as being potential undesirable effects, however the results for several suggested they were in fact desirable effects:</td>
<td></td>
</tr>
<tr>
<td>☐ Trivial</td>
<td>Total cholesterol: MD –0.23 mmol/L (95% CI: –0.32, –0.14)</td>
<td></td>
</tr>
<tr>
<td>☐ Small</td>
<td>LDL cholesterol: MD –0.13 mmol/L (95% CI: –0.21, –0.05)</td>
<td></td>
</tr>
<tr>
<td>☐ Moderate</td>
<td>HDL cholesterol (HDL): MD –0.02 mmol/L (95% CI: –0.03, 0.00)</td>
<td></td>
</tr>
<tr>
<td>☐ Large</td>
<td>Triglycerides: MD 0.01 mmol/L (95% CI: –0.05 to 0.07)</td>
<td></td>
</tr>
<tr>
<td>☐ Varies</td>
<td>Total cholesterol/HDL cholesterol ratio: MD –0.05 (95% CI: –0.14, 0.04)</td>
<td></td>
</tr>
<tr>
<td>■ None identified/don’t know</td>
<td>Systolic blood pressure: –0.75 mmHg (95% CI: –1.42, –0.07)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diastolic blood pressure: –0.52 mmHg (95% CI: –0.95, –0.09)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Quality of life: MD 0.04 (95% CI: 0.01, 0.07; on a scale of 0 to 10, with 0 being worst and 10 best)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Although originally assessed as potential undesirable effects, total and LDL cholesterol, and systolic and diastolic blood pressure were all suggestive of desirable effects.</td>
<td></td>
</tr>
</tbody>
</table>

### Certainty of evidence

<table>
<thead>
<tr>
<th>Certainty of evidence</th>
<th>Research evidence</th>
<th>Additional considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>What is the overall certainty in the evidence of effects?</strong></td>
<td>The overall certainty of the evidence for effects in adults of reduced fat intake is high. Certainty of the evidence for individual outcomes except those listed below are high: Percentage of body fat: moderate Quality of life: low</td>
<td>See GRADE evidence profiles for certainty of evidence for all outcomes (Annex 6).</td>
</tr>
<tr>
<td>☐ Very low</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Low</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≈ High</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ No included studies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Values

<table>
<thead>
<tr>
<th>Values</th>
<th>Research evidence</th>
<th>Additional considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Is there important uncertainty about or variability in how much people value the main outcomes?</strong></td>
<td>The recommendations in this guideline place a high value on reducing risk of mortality, overweight, obesity and subsequently NCDs, and although individuals almost universally value the prevention of premature mortality, those that may be affected by the recommendation may value the benefit of reducing risk of obesity and associated disease differently based on personal preferences, beliefs and customs. For example, because CVDs are a high profile public health topic, including in many LMICs where they represent a growing threat (6), it is expected that most individuals would value efforts to reduce risk; however, in real-world settings, perception of the risk varies considerably (7–11) and therefore may require outreach and communication efforts to improve understanding. Similarly, although many in LMICs are increasingly aware of negative health effects associated with being overweight or obese, some cultures still consider overweight to be a desirable or positive attribute (12–14), others believe body weight to be hereditary and therefore not amenable to management via lifestyle changes (11, 15), and many, regardless of personal beliefs, incorrectly perceive their own body weight in the context of overweight and obesity (i.e. they believe they are at a healthy body weight when in fact they are overweight or obese according to accepted standards for assessing body weight outcomes) (11, 15, 16).</td>
<td></td>
</tr>
<tr>
<td>Judgement</td>
<td>Research evidence</td>
<td>Additional considerations</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Balance of effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the balance between desirable and undesirable effects favour the intervention or the comparison?</td>
<td>Although the effects observed for body measures of body fatness were small to modest in magnitude, they were highly significant and resistant to sensitivity analyses. No undesirable effects were observed as measured by blood lipids, blood pressure and quality of life, and in fact small improvements were observed for total cholesterol, LDL cholesterol and blood pressure. The effect observed for body fatness is expected to make a positive impact on unhealthy weight gain, particularly when paired with other healthy diet and lifestyle interventions. Therefore, as reviewed directly in this body of evidence, the desirable effects strongly outweighed the (non-existent) undesirable effects. However, the NUGAG Subgroup on Diet and Health acknowledged that some individuals who reduce their fat intake might replace some of the energy from dietary fat with energy from foods that are undesirable from a dietary quality perspective, such as free sugars (17), reducing the net benefit. It was also noted that reducing total fat intake might lead to undesirable effects in those who are undernourished; however, as noted in the remarks, special consideration must be given to undernourished individuals and in some such cases the recommendations may not be appropriate. However, in the general population it was felt that the balance between desirable and undesirable effects favours the intervention.</td>
<td></td>
</tr>
</tbody>
</table>

| Resources required | | |
| How large are the resource requirements of the intervention? | Absolute costs of translating the recommendation in this guideline into policies and actions will vary widely depending on which approaches are taken, but in cases where this can be coupled to existing efforts to promote healthy diets such as food-based dietary guidelines, costs may be minimized. Implementation of the recommendation will probably require consumer education and public health communications, some or all of which can be incorporated into existing public health nutrition education campaigns and other existing nutrition programmes at the global, regional, national and subnational levels. | An assessment of the costs of all possible ways of implementing the recommendation is beyond the scope of this guideline, and in any case, there is very little published evidence for costs of possible actions specifically targeting total fat reduction. |

| Certainty of evidence of required resources | | |
| What is the certainty of the evidence of resource requirements (costs)? | No studies assessing the resource requirements were identified. | |

**Annex 7. Evidence to recommendations table**
<table>
<thead>
<tr>
<th>Judgement</th>
<th>Research evidence</th>
<th>Additional considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Does the cost effectiveness of the intervention favour the intervention or the comparison?</strong></td>
<td>Whether or not implementing the recommendation is cost effective is not conclusively known given the various ways that it can be implemented, however given the escalating costs of long-term health care for conditions and diseases associated with overweight and obesity, implementing the recommendation may be associated with long-term savings in costs of health care.</td>
<td>This question can’t be answered with certainty because it requires an assessment of the different, individual modes of implementing the recommendation, which is beyond the scope of this guideline.</td>
</tr>
<tr>
<td>☐ Favours the intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Probably favours the intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Does not favour either</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Probably favours the comparison</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Favours the comparison</td>
<td></td>
<td></td>
</tr>
<tr>
<td>■ Varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>■ No included studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>What would be the impact on health inequity?</strong></td>
<td>The recommendations in this guideline have the potential to reduce health inequity by improving the health of those of lower socioeconomic status as they are generally disproportionately affected by overweight and obesity. However, the effect on equity and human rights would probably be affected by how the recommendations are translated into policies and actions (e.g. fiscal policies and reformulation). The impact of some these previously mentioned interventions on the pricing of manufactured foods would require careful consideration, because any increase in costs borne by manufacturers might be passed on to the consumer, which would be likely to disproportionately affect those of lower socioeconomic status. A reduction in total fat intake may have different impacts on diets depending on what the nature of the dietary fat is in average diets in different settings. For example, in some settings, dietary fat may consist largely of unsaturated fatty acids and a reduction in total fat intake may have an impact on body weight but not CVDs. In settings where dietary fat consists largely of saturated fatty acids and/or trans-fatty acids, a reduction in total fat intake may affect both body weight and CVDs. Because saturated fatty acids and trans-fatty acids can make up a larger percentage of total fat intake in some LMICs (18), in those settings reducing total fat intake might result in health benefits in terms of both body weight and cardiovascular health.</td>
<td>Little to no published evidence from which to draw.</td>
</tr>
<tr>
<td>☐ Reduced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>■ Probably reduced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Probably no impact</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Probably increased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>■ Varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Don’t know</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Judgement Research evidence Additional considerations

#### Is the intervention acceptable to key stakeholders?

<table>
<thead>
<tr>
<th>No</th>
<th>Probably no</th>
<th>Probably yes</th>
<th>Yes</th>
<th>Varies</th>
<th>Don’t know</th>
</tr>
</thead>
</table>

The recommendations in this guideline are in line with many existing national dietary guidelines and policies; however, acceptability may vary across different countries and cultural contexts.

Acceptability may be influenced by:

- how the recommendations are translated into policies and actions (e.g. nutrition labelling policies, marketing policies, fiscal policies and reformulation) because some may be more acceptable than others;
- level of awareness of the health problem that overweight and obesity pose (e.g. it may be less acceptable in settings where awareness is low);
- potential impact on national economies; and
- compatibility with existing policies.

At an individual level, for those who acknowledge the evidence linking total fat intake to unhealthy weight gain and value reducing the risk of unhealthy weight gain, acceptability should be high because overweight and obesity are a significant, recognized global health problem. As noted with respect to feasibility, however, there are many for whom the recommendation will not be acceptable based on the popular perception that high fat diets are healthy, particularly with respect to losing weight or maintaining a healthy body weight (19).

#### Is the intervention feasible to implement?

<table>
<thead>
<tr>
<th>No</th>
<th>Probably no</th>
<th>Probably yes</th>
<th>Yes</th>
<th>Varies</th>
<th>Don’t know</th>
</tr>
</thead>
</table>

As noted elsewhere in the guideline, implementing the recommendations in this guideline can be achieved in numerous ways (e.g. behaviour change interventions, fiscal policies, regulation of marketing foods and beverages, product labelling schemes, and reformulation of manufactured products), with feasibility varying depending on approach. Regardless of specific modes of implementation, the recommendations can be incorporated into existing activities designed to promote healthy diets. For example, appropriate messaging on total fat intake can readily be added to existing food-based dietary guidelines and behaviour change and education campaigns.

In settings where efforts to reduce total fat intake are planned or are already underway, feasibility should be much higher than in settings where plans are not yet in place. Regardless, feasibility will be influenced by the existing, relevant infrastructure (for different interventions) and resources available.

Relevant to all interventions, widespread use and availability of certain food items high in fat may pose challenges in decreasing consumption where necessary to meet the recommended intake. Regardless of which interventions are employed to realize the recommended fat intake, some amount of behaviour change at the individual level will be required. This may be challenging in some settings, particularly those in which popular opinion has currently been shaped to view high fat intake as healthy, particularly with respect to losing weight or maintaining a healthy body weight (19).
References for Annex 7


